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Zusammenfassung           
 
Die meisten Menschen stellen sich unter „Rheuma“ altersbedingte Schmerzen in den Gelenken 
und durch Abnutzung verursachte Bewegungseinschränkung vor. Arthrose (oder Osteoarthritis) ist 
aber nur eine der vielen rheumatischen Erkrankungen, von denen allein in der Schweiz ca. 1,5 
Millionen Menschen betroffen sind. Dabei ist „Rheuma“ keine Alterskrankheit. Dass alltägliche 
Bewegungsabläufe wie Kochen oder einen Brief schreiben zur schmerzhaften Herausforderung 
werden, kennen auch viele jüngere Menschen. Die rheumatoide Arthritis zum Beispiel, die häufigste 
entzündliche Gelenkserkrankung, tritt typischerweise ab dem dritten bis fünften Lebensjahrzehnt auf. 
Der Krankheitsverlauf ist meist chronisch und nur wenige Patienten können geheilt werden. Damit 
stellen die Krankheiten des rheumatischen Formenkreises nicht nur eine große individuelle Belastung 
dar, sondern verursachen auch enorme Kosten durch Arbeitsausfälle, medizinische Behandlungen, 
Begleiterkrankungen und z.T. auch eine verringerte Lebenserwartung. 
 
Die rheumatoide Arthritis (RA) ist eine chronisch-entzündliche Systemerkrankung, die vor 
allem die Gelenke betrifft. Die fortschreitende Zerstörung von Gelenksknorpel und Knochen bereitet 
den Patienten große Schmerzen und eine zunehmende  Bewegungseinschränkung. Eine wichtige Rolle 
bei der Krankheitsentstehung spielt das Immunsystem, welches sich gegen die körpereigenen 
Gelenkstrukturen  richtet und gemeinsam mit lokalen Gelenkszellen Knorpel und Knochen angreift. 
Bei RA handelt es sich somit um eine Autoimmunerkrankung. Synoviale Fibroblasten (SF), also 
Bindegewebszellen in der Gelenkskapsel (Synovialis), sind in der RA die wichtigsten Zellen, die den 
Knorpelabbau vorantreiben; diese „RASF“ schütten knorpel-abbauende Enzyme aus, dringen tief in 
das Knorpelgewebe ein und unterhalten durch die Produktion von entzündlichen Signalmolekülen die 
chronische Gelenksentzündung. Da die RASF diese Eigenschaften auch zeigen, wenn sie aus der 
chronisch-entzündlichen Umgebung des RA-Gelenks herausgenommen werden (d.h. ohne weitere 
Stimulation ausserhalb des Körpers kultiviert werden), spricht man auch von einem aktivierten 
Phänotyp. Es gibt verschiedene molekulare Ursachen für diesen aktivierten Phänotyp, u.a. das 
Anschalten von Onkogenen (d.h. von Genen, welche die Entstehung und das Wachstum von Tumoren 
fördern) und das Ausschalten der entsprechenden Gegenspieler, der Tumorsuppressoren. Aus der 
Krebsforschung ist bekannt, dass für diese Veränderungen oft epigenetische Mechanismen 
verantwortlich sind. Das sind Vorgänge, die die Genexpression beeinflussen ohne dabei die Sequenz 
des genetischen Materials, der DNA, zu verändern, und die dennoch während der Zellteilung vererbt 
werden können. Genauer gesagt wird das Chromatin (die Speichereinheit der DNA in der Zelle 
bestehend aus DNA und Histonproteinen) durch verschiedene chemische Modifikationen lokal so 
verändert, dass Genexpression zugelassen oder unterbunden wird. 
Eine weitere Instanz der Kontrolle der Genexpression, deren Bedeutung in den letzten Jahren 
immer deutlicher geworden ist, sind winzige RNA-Moleküle – microRNAs – von denen es über 
tausend verschiedene in menschlichen Zellen gibt. Eine bestimmte microRNA kann bis zu mehrere 
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hundert unterschiedliche Gene kontrollieren und somit das Verhalten von Zellen entscheidend 
beeinflussen. 
Seit einigen Jahren gibt es immer mehr Hinweise dafür, dass der aktivierte Phänotyp der RASF 
durch epigenetische Veränderungen einerseits und durch die Fehlregulation verschiedener microRNAs 
andererseits bedingt wird. In meiner Doktorarbeit habe ich mich daher auf zwei bekannte Onkogene 
aus dem Feld der Epigenetik und aus dem Gebiet der miRNAs konzentriert, um deren Rolle in der 
Aktivierung der RASF zu untersuchen. 
Im ersten Projekt habe ich die Histonmethyltransferase Enhancer of Zeste homologue 2 (EZH2) 
untersucht, die die Aktivität ihrer Zielgene durch Methylierung des Histon 3 an Lysinrest 27 (H3K27) 
unterdrückt. Ich konnte zeigen, dass RASF erhöhte Mengen von EZH2 exprimieren und dies durch 
Stimulation mit entzündlichen Signalstoffen (tumour necrosis factor α [TNFα]) noch verstärkt werden 
konnte. Ich konnte weiterhin herausfinden, dass EZH2 in RASF die Expression eines wichtigen 
Inhibitorproteins unterdrückt, das secreted frizzled-related protein 1 (sFRP-1). Der Genpromoter von 
SFRP1 weist in RASF eine stärkere Methylierung von H3K27 auf und deshalb wird die Produktion 
von sFRP-1 unterbunden. Somit kann sFRP-1 den Wnt-Signalweg nicht mehr effektiv hemmen. 
Dieser ist in RASF aktiviert und trägt massgeblich zum aktivierten Phänotyp der RASF bei. Damit 
konnte ich mit diesem Projekt aufzeigen, dass die Histonmethyltransferase EZH2 durch epigenetische 
Regulation einen wichtigen Signalweg in der Pathogenese der RA beeinflusst. 
Im zweiten Projekt beschäftigte ich mich mit einem microRNA-Cluster, der eine wesentliche 
Rolle im Immunsystem spielt und der, wenn er in bestimmten Immunzellen zu stark exprimiert wird, 
Autoimmunität hervorrufen kann. Dieser microRNA-Cluster – miR-17-92 – kodiert für sechs 
verschiedene microRNAs, die alle unterschiedliche Zielgene haben. In RASF wird die Expression von 
miR-17-92 durch Stimulation mit TNFα aktiviert, wobei dies vom NF-κB Signalweg abhängig war, 
einem der wichtigsten entzündlichen Signalwege, die bei RA dauerhaft aktiv sind. Um 
herauszufinden, welche Rolle einzelne microRNAs dieses Clusters in der Aktivierung der RASF 
spielen, wurden diese künstlich (d.h. durch Transfektion) in RASF eingebracht. Dabei konnte ich 
feststellen, dass miR-18a spezifisch die Expression von knorpel-abbauenden Enzymen und 
entzündlichen Mediatoren in RASF verstärkte. Mit Hilfe von Computer-basierten 
Vorhersageprogrammen wurden verschiedene mögliche Zielgene der miR-18a ermittelt. Durch die 
anschliessende experimentelle Validierung konnte der NF-κB-Signalweg-Inhibitor TNFα-induced 
protein 3 (TNFAIP3) als neues Zielgen der miR-18a identifiziert werden. Die Transfektion von miR-
18a verstärkte somit das NF-κB-Signal in RASF. Zusammenfassend konnte so ein neuer positiver 
Feedback-Mechanismus entdeckt werden, bei dem TNFα den NF-κB-Signalweg wie auch die miR-
18a induziert, wobei die miR-18a über die Hemmung des NF-κB-Inhibitors TNFAIP3 zu einer 
zusätzlichen Verstärkung des NF-κB-Signalwegs führt. 
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Summary            
 
Most people associate “rheumatism” with age-related degenerative joint lesions leading to pain 
and limited mobility. Osteoarthritis, however, is only one of the many rheumatic diseases affecting 1.5 
million people alone in Switzerland. Rheumatism is not restricted to diseases of the elderly. Even for 
younger people affected by these disorders activities of daily living such as cooking or writing a letter 
can become a painful challenge. The age at onset for rheumatoid arthritis (the most common 
inflammatory joint disease), for instance, is between the third and fifth decade of life. The course of 
the disease usually is chronic and only few patients can be cured. Thus, the rheumatic diseases do not 
only represent a great individual burden but also impose enormous costs upon society because of lost 
working hours, medical treatments, comorbidities and in some cases a reduced life expectancy. 
 
Rheumatoid arthritis (RA) is a chronic-inflammatory systemic disease mainly affecting the 
articular joints. The progressive destruction of articular cartilage and bone causes pain and an 
increasing restriction of mobility. The immune system assumes an important role in the pathogenesis 
of RA; it turns against the body’s own joint structures and, together with local synovial cells, attacks 
cartilage and bone. These processes define RA as an autoimmune disease. Synovial fibroblasts (SF), 
connective tissue cells of the joint capsule (synovium), are the major drivers of cartilage degradation 
in RA; these “RASF” secrete cartilage-degrading enzymes, invade deeply into the cartilage and 
maintain the chronic joint inflammation by the production of inflammatory signalling molecules. 
Since RASF retain these features even when they are taken out of the chronic-inflammatory 
environment of the RA joint (i.e. being cultivated outside the body without further stimulation) they 
are said to show an activated phenotype. This activated phenotype is based on several molecular 
aberrations, amongst others the activation of oncogenes (i.e. genes promoting the development and 
growth of tumours) and the switching-off of the respective opponents, the tumour suppressors. From 
cancer research it is known that these changes are often caused by epigenetic mechanisms. These are 
processes that influence gene expression without modifying the sequence of the genetic material, the 
DNA, but still may be inherited during cell division. More precisely, the structure of the chromatin 
(the storage unit of DNA in a cell consisting of DNA wrapped around histone proteins) is locally 
altered by different chemical modifications in such a way that gene expression is either permitted or 
restricted. 
In recent years yet another instance of controlling gene expression has attracted growing 
attention: tiny RNA molecules – the microRNAs. A human cell can express more than thousand 
different microRNAs and one microRNA can control the expression of up to several hundreds of 
genes. Thus, microRNAs may significantly influence the behaviour of cells. 
Epigenetic changes and the dysregulation of several microRNAs have been emerging as 
possible causes for the activated phenotype of RASF. During this doctoral thesis I have concentrated 
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on two well-known oncogenes from the epigenetics and the microRNA fields to investigate their role 
in the activation of RASF.  
In the first project, I studied the histone methyltransferase Enhancer of Zeste homologue 2 
(EZH2) which represses the activity of its target genes by methylating histone 3 at lysine 27 (H3K27). 
I could show that RASF express increased levels of EZH2 and that EZH2 is further inducible by 
stimulation with inflammatory mediators (i.e. tumour necrosis factor α [TNFα]). Furthermore, I could 
reveal that in RASF, EZH2 represses the expression of an important inhibitor protein, the secreted 
frizzled protein 1 (sFRP-1). The gene promoter of SFRP1 in RASF presents with stronger H3K27 
methylation and hence the production of sFRP-1 is impaired. As a consequence, sFRP-1 cannot 
effectively inhibit the Wnt signalling pathway which is activated in RASF and decisively contributes 
to the activated phenotype of RASF. In conclusion, with this project I could show that through 
epigenetic regulation the histone methyltransferase EZH2 manipulates an important signalling 
pathway in the pathogenesis of RA.  
Within the second project I addressed a microRNA cluster that plays a fundamental role in the 
immune system and, if overexpressed in certain immune cells, causes autoimmunity. This microRNA 
cluster – miR-17-92 – codes for six different microRNAs all of them having different target genes. In 
RASF, stimulation with TNFα activates the expression of miR-17-92. This was dependent on the NF-
κB pathway, one of the most important inflammatory signalling pathways stably activated in RA. To 
elucidate the role of individual microRNAs from this cluster in the activation of RASF these were 
artificially introduced into RASF (i.e. by transfection). This allowed me to observe that miR-18a 
specifically enhanced the expression of cartilage-degrading enzymes and inflammatory mediators in 
RASF. With the help of computational prediction programmes various potential miR-18a target genes 
were sought. By subsequent experimental validation I could identify the NF-κB signalling inhibitor 
TNFα-induced protein 3 (TNFAIP3) as a novel target gene of miR-18a. Since TNFα is a major 
activator of NF-κB signalling in RASF this work discovered a new positive feedback mechanism: 
TNFα induces NF-κB activity and, thus, miR-18a which in turn represses the NF-κB inhibitor 
TNFAIP3 which further enhances NF-κB signalling in RASF.  
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1. Rheumatoid arthritis 
 
Rheumatoid arthritis (RA) is a chronic autoimmune disease of the synovial joints affecting 0.5 
to 1% of the population worldwide (1, 2). It is characterised by the persistent activation of the immune 
system, a continuous influx of immune cells into the joint and the activation of resident joint cells to 
degrade articular cartilage and bone. As a result, joints are progressively destroyed and become 
functionally impaired.  
As with many other autoimmune diseases, RA is more common in women than in men. In a 
recent epidemiological study, the lifetime risk to develop RA was found to be 3.6% for women and   
1.7% for men (3). The reason for the female preponderance is unresolved although sex hormones, 
microchimerism (i.e. the persistence of foetal cells in the mother) and X chromosome inactivation 
have been implicated (4, 5). There are significant regional differences in prevalence ranging from 0.2 
to 5% between different continents and within countries pointing towards the involvement of 
environmental factors in the development of RA (6, 7). Despite decades of research in the field of RA 
the cause for this progressive and incurable disease has not yet been uncovered. It is generally 
accepted that a combination of genetic predisposition, environmental influences and possibly 
infectious agents lead to the development of RA. The best established genetic risk factor for RA is 
certain alleles of the human leukocyte antigen direct repeat B1 (HLA-DRB1) locus encoding the so-
called shared epitope which is thought to break self-tolerance during antigen presentation (8, 9). Other 
well-established risk loci are the protein tyrosine phosphatase non-receptor type 22 (PTPN22), 
peptidylarginine deiminase type 4 (PADI4), cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and 
TNFα-induced protein 3 (TNFAIP3) genes. On a molecular level, the basis for the genetic association 
with RA is currently not clear for most of the genes; the majority of them are, however, connected to 
function or regulation of the immune system implying an actual functional role for these gene 
polymorphisms (9). Interestingly, there is also one HLA-DRB1 allele (HLA-DRB1*1301) that confers 
protection from RA and is enriched in the healthy population (10). Despite the indisputable genetic 
association with RA the concordance rates for monozygotic twins are only ~15% and even less (~5%) 
for dizygotic twins (11). Therefore, other factors must play a role in the development of RA. Infection 
with certain viruses (e.g. Epstein-Barr virus [EBV] and retroviruses) or bacteria may have an influence 
on the pathogenesis of RA. The connection seems to be especially strong to periodontal disease as the 
bacterium Porphyromonas gingivalis expresses PADI4 and may therefore contribute to the generation 
of autoantigens (namely citrullinated proteins) (2, 12). Important contributors to RA are environmental 
influences, most importantly exposure to tobacco smoke. Especially smoking individuals carrying the 
shared epitope are considerably at risk to develop RA (13). Other factors may similarly decrease (e.g. 
consumption of alcohol, vitamin D intake and oral contraceptives) or increase (e.g. ingestion of red 
meat) the susceptibility to RA (13). 
Chapter I – Introduction 
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The socioeconomic and individual burden of RA is high. Because of the progressive joint 
destruction and systemic inflammation RA patients suffer from pain and disability as well as extra-
articular comorbidities such as an increased risk to develop cardiovascular disease and depression. The 
consequences are a reduced quality of life in general, increased mortality, social isolation and high 
costs for the health care systems (8).  
The diagnosis of RA is based on the American College of Rheumatology (ACR)/European 
League against Rheumatology (EULAR) classification criteria for rheumatoid arthritis of 2010 (14, 
15). Patients presenting with joint swelling (i.e. active synovitis) and whose synovitis cannot be 
explained by any other diagnoses are eligible to be tested according to the criteria given in Table 1. 
 
Table 1 The 2010 ACR/EULAR classification criteria for RA (adapted from Aletaha D et al. (14, 15)) 
 
Classification criteria for RA (score-based algorithm: add score of categories A-D) 
a score of >6/10 is needed for classification of a patient as having definite RA 
 
Score 
A. Joint involvement   
 1 large joint 0 
 2-10 large joints 1 
 1-3 small joints (with or without involvement of large joints) 2 
 4-10 small joints (with or without involvement of large joints) 3 
 ≥10 joints (at least 1 small joint) 5 
B. Serology (at least one test result is needed for classification)  
 negative RF and negative ACPA 0 
 low-positive RF or low-positive ACPA 2 
 high-positive RF or high-positive ACPA 3 
C. Acute-phase reactants (at least one test result is needed for classification)  
 normal CRP and normal ESR 0 
 abnormal CRP or abnormal ESR 1 
D. Duration of symptoms  
 <6 weeks 0 
 ≥6 weeks 1 
 
RF = rheumatoid factor; ACPA = anti-citrullinated protein antibody; CRP = C-reactive protein;  
ESR = erythrocyte sedimentation rate 
 
These new criteria allow for an earlier diagnosis and, therefore, prompt and more rigorous intervention 
than the previous classification criteria of 1987 (16) which only diagnosed RA when patients already 
presented with the chronic erosive disease (14, 15). Thus, the current strategy is to initiate treatment as 
early as possible to prevent joint damage, suppress inflammation, control comorbidities and limit 
complications with the aim of achieving remission or even cure (17). One major concern with the new 
2010 classification criteria is the problem of specificity meaning that patients might be misclassified as 
having RA when in fact having another disease (false-positive result) (18). As a consequence, 
biological samples from the early diagnosed RA patients (such as synovial tissue specimens) are more 
heterogeneous which might complicate their use in basic research studies. Human material used in this 
doctoral thesis has been obtained from RA patients diagnosed on the basis of the 1987 criteria. In 
Chapter I – Introduction 
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summary, the new classification criteria have to be considered in the light of early diagnosis and 
treatment intervention coming at the cost of reduced specificity (18). 
After the diagnosis of RA, a disease-modifying antirheumatic drug (DMARD), usually 
methotrexate (MTX), is given as first-line treatment (8). Additionally, patients may receive a second 
DMARD or a biological agent in combination. In contrast to DMARDs and biologicals which limit 
joint swelling, systemic inflammation and joint destruction analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs) merely treat the symptoms of RA, namely pain and stiffness (8). 
Glucocorticoids are indicated for short-term use only during flare-ups or locally (i.e. intra-articular) for 
particularly active joints because of the substantial unwanted effects they cause (8). The use of 
biologicals has revolutionised RA treatment in the last decades; blocking cytokines/cytokine signalling 
and immune cell activation has been shown to be highly effective in limiting the progression of RA. 
Currently in clinical use are biologicals that block tumour necrosis factor (TNF)-α (Adalimumab, 
Certolizumab pegol, Etanercept, Golimumab and Infliximab), interleukin (IL)-1β (Anakinra) and IL-6 
(Tocilizumab), inhibit T cell activation (Abatacept) and deplete B cells (Rituximab). Other strategies 
targeting for example IL-17, IL-23/IL-12-p40 or IL-15 are under investigation (17). As alternative to 
MTX and other DMARDs such as hydroxychloroquine, sulfasalazine and leflunomide, new small 
molecule inhibitors of intracellular kinases such as Janus kinase (JAK) or spleen tyrosine kinase 
(SYK), are in development to be used as novel DMARDs (8). 
Despite all the progress that has been made in the treatment of RA principal obstacles are yet to 
be overcome. Although remission is achieved more frequently RA remains an incurable disease. 
Therefore, patients need to have regular examinations and take life-long medication (8). Often, disease 
flare-ups cannot be prevented and in many cases, drugs have significant unwanted effects, for instance 
higher susceptibility to opportunistic infections, in particular to mycobacterial disease under TNFα 
blockade. Since biologicals are extremely expensive their cost-effectiveness is a matter of debate and 
the search for more affordable alternatives is on-going. Finally, there are still a considerable number of 
patients who do not or insufficiently respond to therapy (2, 8). For these reasons, research to find the 
cause of RA, to better understand its pathogenesis and to develop novel therapies targeting the disease 
must continue. 
 
Pathogenesis –many components in a multifactorial disease 
 
Rheumatoid arthritis is a very complex disease with various cell types and biological processes 
involved. Beside immune cells immigrating from the blood stream resident joint cells (i.e. fibroblasts, 
macrophages, chondrocytes, endothelial cells and osteoclasts) act in perpetuating joint inflammation 
and executing cartilage and bone destruction.  
The capsule of healthy diarthrodial joints is lined by a thin synovial membrane (the synovium) 
consisting of the 1-2 cells strong lining layer (composed of macrophages - type A - and fibroblasts - 
Chapter I – Introduction 
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type B synoviocytes) and a rather a-cellular sublining mainly made up of loose connective tissue. The 
function of the synovium is lubrication of the joint cavity and supplying chondrocytes with nutrition 
and oxygen (19, 20). In RA, the lining layer thickens (up to 15 cell layers), the sublining is populated 
by immune cells attracted from the circulation and angiogenesis (i.e. the formation of new blood 
vessels) takes place. Altogether, these mechanisms lead to the formation of the destructive pannus 
tissue (1, 2, 19) (Figure 1). Resident and immigrated cells in the synovium cooperate in perpetuating 
joint inflammation and damage as summarised in Figure 2 (2). 
 
 
Figure 1 Schematic representation of a healthy and a RA joint 
In RA, proliferation and reduced apoptosis of cells within the synovial membrane as well as continuous 
extravasation of circulating immune cells into the joint tissue lead to the formation of pannus tissue that destroys 
cartilage and bone. 
 
 The autoimmune reaction inside the rheumatoid joint comprises the innate and the adaptive 
compartment. The innate immune response, apart from anatomical barriers like skin and mucous 
membranes, is the first line of defence against pathogens and provides the basis for the antigen-
specific reactions of the adaptive immune system (as procured by the action of B and T cells). 
Pathogen-associated molecular patterns (PAMPs) derived from the intruder (e.g. DNA, RNA, 
peptidoglycan) activate pattern-recognition receptors (PRRs) on the surface of innate immune effector 
cells and initiate a cascade of events including the secretion of cytokines and chemokines, activation 
of the complement system, extravasation to the site of infection, pathogen clearance by phagocytosis, 
killing of virus-infected cells, and lastly, antigen presentation to activate adaptive mechanisms of 
defence (21). The major innate immune cells inside the RA joint are macrophages, but natural killer 
cells, mast cells, neutrophil granulocytes, and dendritic cells are abundant as well (2). Mast cells, best 
known for the release of histamine during allergic reactions, are implicated in cytokine production and 
neutrophil recruitment to the RA synovium (22). Neutrophils, which are mainly found in the synovial 
fluid of RA patients, are defective in apoptosis and release high amounts of reactive oxygen and nitro-  
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Figure 2 Pathogenic processes in the RA joint mediated by different cell types (from McInnes IB 
and Schett G (2))  
Inside the RA synovium, resident cells as well as cells of the innate and the adaptive immune system promote 
chronic inflammation and joint destruction.  Locally produced inflammatory cytokines and chemokines activate 
and attract leukocytes from the blood stream. Synovial fibroblasts and osteoclasts actively destroy cartilage and 
bone. The increased metabolic demand causes hypoxia which initiates angiogenesis allowing the influx of an 
even greater amount of immune cells. Hypoxia, degradative and apoptotic processes generate DAMPs to further 
activate cells in the synovium altogether generating a vicious cycle of mutual activation of resident and 
immigrated cells of the joint.  
Abbreviations: ADAMTS a disintegrin and metalloprotease with thrombospondin-1-like domains, DAMP 
damage-associated molecular pattern, Dkk-1 Dickkopf-1, FcR Fc receptor, FcεRI high affinity IgE receptor, 
FGF fibroblast growth factor, GM-CSF granulocyte-macrophage colony-stimulating factor, HA hyaluronan, 
HSP heat-shock protein, IFN-α/β interferon-α/β, MMP matrix metalloproteinase, NLR nucleotide-binding 
oligomerization domain-like receptor, PAMP pathogen-associated molecular pattern, PAR2 protease-activated 
receptor 2, PDGF platelet-derived growth factor, RANKL receptor activator of nuclear factor κB ligand, TGF-β 
transforming growth factor β, Th0 type 0 helper T cell, Th1 type 1 helper T cell, Th17 type 17 helper T cell, 
TLR toll-like receptor, TNF-α tumour necrosis factor α, VEGF vascular endothelial growth factor 
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gen species (ROS and RNS) as well as proteases and inflammatory mediators thereby augmenting 
synovial inflammation and tissue injury (2, 23). Dendritic cells (DC) are the major professional 
antigen-presenting cells (APCs) which, following their activation, start to differentiate and migrate to 
the lymphoid tissues where they display antigens via the major histocompatibility complex (MHC) 
molecules to effector cells (24). The role of DC in RA pathogenesis is ambiguous; depending on the 
subset they may be involved in maintaining (plasmacytoid DC) or breaking (classical DC) self-
tolerance, and numbers of circulating DC (both plasmacytoid and classical) were differentially 
modulated by various therapeutic interventions in RA patients (24). 
 Macrophages (Mφ) are tissue-specific monocyte-derived phagocytes specialised in the removal 
of pathogens and cellular debris. They are key producers of the most crucial RA-associated cytokines 
– TNFα, IL-1β and IL-6. Targeting Mφ and their products has proven especially successful in treating 
RA; Mφ numbers in the sublining were shown to be reduced by DMARDs such as MTX or 
leflunomide and TNFα antagonists (24). Similarly, blocking IL-1β or IL-6 significantly improves the 
disease course. These facts underpin the importance of Mφ in the pathogenesis of RA. Elevated 
numbers of Mφ in the RA synovium contribute to joint destruction at several levels: beside a plethora 
of cytokines they are also a source of chemokines attracting more immune cells from the blood stream, 
they release ROS, RNS and matrix-degrading enzymes, phagocytose and present antigen, and drive 
bone erosions after differentiating into osteoclasts (2, 25, 26). Healthy bone is constantly remodelled by 
the simultaneous action of bone-forming osteoblasts and bone-resorbing osteoclasts. In RA, this 
finely-tuned balance is skewed towards an overrepresentation of osteoclasts and therefore undue bone 
resorption (27). In the presence of certain stimuli, in particular macrophage-colony stimulating factor 
(M-CSF) and receptor activator of nuclear factor κB ligand (RANKL), hematopoietic stem cells 
differentiate towards the monocytic/macrophage lineage to form osteoclast progenitor cells which 
finally fuse to become fully differentiated multinucleated osteoclasts (28). In the RA synovium, 
RANKL is abundantly expressed. Together with the high amounts of pro-inflammatory cytokines such 
as IL-6 and TNFα this is thought to cause the imbalance in bone remodelling and articular bone loss in 
RA (27, 28).  
Innate immune cells are activated through the binding of PAMPs to PRRs – toll-like receptors 
(TLRs) and nucleotide oligomerization domain (NOD)-like receptors (NLRs). Different TLRs and 
NLRs are expressed throughout the synovium, not only in Mφ but also in synovial fibroblasts, and 
particularly the expression of TLR2, 3, 4, 7, and 8 as well as NOD2 has been associated with 
proinflammatory and destructive activity (24, 29). The evidence for the presence of actual disease-
causing PAMPs in synovial tissue is scarce; despite the fact that infections may be connected to RA 
pathogenesis and viral or bacterial DNA may be present in synovial tissue these could not clearly be 
pinned down as being true initiators of RA (29). Instead, endogenous ligands for TLRs – damage- or 
danger-associated molecular patterns (DAMPs) – have been found in great variety and abundance. 
These molecules are unleashed upon tissue injury and thus link sterile tissue damage and inflammation 
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(30). DAMPs include but are not limited to heat shock proteins (HSP), lipoproteins such as serum 
amyloid A, alarmins as high-mobility group box-1 protein (HMGB1), self-nucleic acids released from 
necrotic cells, and extracellular matrix (ECM) components (e.g. hyaluronic acid fragments) (30). With 
the enduring tissue destruction in RA there is a sustained supply with DAMPs and thus, the interest in 
developing means of antagonising TLR signalling in RA has resulted in several preclinical and clinical 
trials (29).  
During an infection, the innate immune response is followed by the antigen-specific adaptive 
response mediated by B and T lymphocytes. Aberrant activation of T lymphocytes is a characteristic 
of RA pathogenesis which is also exemplified by the success of therapies inhibiting T cell activation 
(Abatacept) (17). Once the T cell receptor (TCR) interacts with MHC-bound antigens on APCs T cells 
become activated. Additionally, the APC needs to provide costimulatory signals of the B7 family of 
immunoglobulins (cluster of differentiation [CD]80 and CD86) which bind to CD28 and CTLA4 on 
the surface of the T cell (21). Abatacept containing the extracellular part of CTLA4 binds to 
CD80/CD86 and thereby prevents costimulation via CD28 and thus inhibits T cell activation (17). RA 
has classically been viewed as a Th1 disease (i.e. a predominance of cytokines derived from T helper 
cells type 1 [Th1] and paucity of Th2 cytokines) but this view has been challenged by data showing 
beneficial effects of interferon-γ (IFN-γ) and other Th1 cytokines in RA animal models and in vitro 
(31). With the discovery of new T cell subsets, in particular the Th17 and regulatory (Treg) T cells, the 
T cell compartment in RA has regained attention in recent years. Whereas Treg (CD4+CD25+ cells that 
express the transcription factor forkhead box protein P3 [Foxp3]) have immunosuppressive activity 
which appears to be attenuated in RA (32) Th17 (CD4+CD25- cells that uniquely express the 
transcription factors retinoic acid receptor-related orphan receptor-γ-t [RORγt] and RORαt) have 
strong proinflammatory functions. Th17 are a major source of the IL-17 family of cytokines which 
exert pleiotropic functions in the activation of immune cells and synoviocytes, osteoclastogenesis and 
angiogenesis. In this manner, IL-17 directly contributes to the major hallmarks of RA – inflammation, 
joint infiltration, cartilage destruction and bone erosions – and therapeutics targeting IL-17 are 
underway (31).  
 B cells are attracted to the RA joint by locally produced chemokines, and in the synovium they 
are often organised in ectopic germinal centres together with T lymphocytes and dendritic cells (33, 
34). They produce a range of inflammatory cytokines and chemokines and function as APCs for T 
cells thereby contributing to the maintenance of the chronic inflammatory state of the synovium. Their 
main function in RA, however, is the production of autoantibodies (34). Beside the long-known 
association of rheumatoid factor (RF; i.e. autoantibodies directed against an epitope on the constant 
fraction of immunoglobulin G) with the disease, the new classification criteria for RA also include 
other autoantibodies, the anti-citrullinated protein antibodies (ACPA) (14, 15, 33). ACPA-positive RA 
is associated with other genetic risk loci and environmental risk factors than ACPA-negative RA (9, 
13). Patients positive for both ACPA and RF bear a worse prognosis and, thus, ACPA-positive RA 
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may represent a clinical entity distinct from the autoantibody-negative disease (8, 9, 33). B cells in RA 
are currently targeted by Rituximab, a B cell depleting chimeric monoclonal antibody for CD20 (17, 
33). Interestingly, CD20 can only be found on pre-B to mature B cells but not on the antibody-
producing plasma cells and the mode of action of Rituximab may mainly be imputable to the control 
of cytokine production, T cell activation and reduced development of memory B cells after 
repopulation (17, 33).  
 A further pathogenetic feature of RA is dysregulated synovial angiogenesis. Because of the 
constant influx of immune cells alongside increased proliferation and decreased apoptosis of synovial 
cells the metabolic demand inside the synovium outpaces the existing vascular supply (35, 36). Still, 
despite the strong angiogenic drive in the synovial tissue the newly formed vessels appear to have 
maturation defects, i.e. the recruitment of pericytes (mural cells that stabilise the endothelial tubes) is 
compromised which prevents optimal perfusion (37). Therefore, the synovial microenvironment 
remains hypoxic and leaky vessels facilitate constant immune cell infiltration. Together, these events 
result in a vicious cycle of sprouting angiogenesis, hypoxia and immune cell extravasation (35).   
 
Rheumatoid arthritis synovial fibroblasts – the tumour-cell like invasive phenotype 
 
 The work in this doctoral thesis has concentrated on the rheumatoid arthritis synovial fibroblast 
(RASF), and, thus, this section shall be dedicated to this cell type. Considered as an innocent 
bystander for many years RASF are now recognised as the driving force in cartilage destruction in 
RA. The prominent role of RASF in the degradation of articular cartilage became apparent for the first 
time when fibroblasts from different sources (i.e. RA, osteoarthritis [OA] or normal synovium or skin) 
were co-implanted with human cartilage into severe combined immunodeficient (SCID) mice and the 
cartilage was analysed after 60 days (38). In contrast to OA, normal SF or skin fibroblasts RASF were 
able to deeply invade into the cartilage, and this went along with the expression of matrix-degrading 
enzymes and adhesion molecules, particularly at the site of invasion (38). This study proved for the 
first time that RASF are capable of driving tissue destruction independent of a fully functional 
immune system. Ever since, RASF have been the subject of many studies trying to elucidate the 
reasons for their aberrant activation and “transformation”. RASF share many features with malignant 
cells, i.e. defects in controlling proliferation/apoptosis and (local) invasiveness (1, 39, 40). This 
“activated phenotype” of RASF may be a consequence of the increased expression of anti-apoptotic 
molecules (e.g. Bcl family members or the small ubiquitin-like modifier [SUMO]-1) and proto-
oncogenes (e.g. c-Myc) and inactivation of tumour suppressor genes (e.g. p53 or phosphatase and 
tensin homologue [PTEN]) (1, 39). Furthermore, they express a range of adhesion molecules mediating 
their binding to cartilage matrix or cell-cell interactions; these include members of the integrin family, 
vascular-adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1 and cadherin-11 
(19, 41). The similarities of RASF with cancer cells and the invasive behaviour of the pannus tissue 
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might allow for RA to be viewed as a locally invasive tumour with RASF being described as tumour-
cell like or transformed (1, 20, 42). Interestingly, the importance of the migratory/invasive RASF in the 
pathogenesis of RA has recently been further substantiated by data demonstrating that RASF injected 
subcutaneously into SCID mice migrate towards and invade into co-implanted human cartilage at 
distant sites (43) which was interpreted as a form of metastasis by the authors (44). Despite the fact 
that nowadays we know a lot about the imprinted phenotype of RASF the molecular mechanisms 
responsible for the transition from the healthy to the RASF are largely unknown (45). 
 Additionally to their apparent intrinsic activation, RASF can be stimulated by a great range of 
inflammatory mediators (i.e. cytokines and chemokines), TLR ligands, cartilage and ECM 
components, as well as the direct physical interaction with immune and other cells, all of which can be 
found  in the RA synovium (19). The result of RASF activation is the production and secretion of 
matrix metalloproteinases (MMPs) and other cartilage-destructive molecules, and pro-inflammatory 
cytokines and chemokines acting in autocrine and paracrine ways to fuel joint inflammation and 
destruction (19). Some especially important activators and products of RASF are shown in Table 2. 
 
Table 2 Stimuli activating RASF and pro-inflammatory and matrix-degrading molecules produced by 
RASF (adapted from Noss EH & Brenner MB (19)) 
 
RASF activators 
 
RASF products  
  
  
cytokines (TNFα, IL-1β, IL-6, IL-17, IFN-γ, IL-18) 
 
cytokines (IL-6, IL-15, IL-23, type I interferons) 
growth factors (FGF, PDGF, TGF-β) 
 
growth factors (GM-CSF, VEGF, TGF-β, PDGF) 
chemokines (CCL-2, CCL-5, CCL-13, CXCL-12, 
 CX3CL-1) 
 
chemokines (CXCL-1, -5, -6, -8, -9, -10, -11, -12, -12, 
 CCL-2, -3, -5, CX3CL-1) 
bioactive lipids (prostaglandins, leukotrienes) 
 
bioactive lipids (prostaglandins) 
cell surface ligand interactions (CD40/CD40L,  
VLA-4/VCAM-1, LFA-1/ICAM-1) 
 
cell surface receptors (CD40, VCAM-1, ICAM-1,  
TLRs, integrins, cytokine and chemokine receptors) 
tissue degradation products (DAMPs, fibronectin  
and thrombin fragments, microparticles) 
 
degradative enzymes (MMPs, cathepsins) 
hypoxia     
FGF = fibroblast growth factor, GM-CSF = granulocyte-macrophage colony-stimulating factor, LFA-1 = 
lymphocyte function-associated antigen-1, PDGF = platelet-derived growth factor, TGF-β = transforming 
growth factor β, VLA-4 = very late antigen-4 
 
As resident cells of the synovium, RASF get into bidirectional contact with all other synovial 
cells (local and immigrated), either directly via cell surface interactions or indirectly via secreted 
products (reviewed in 19) (Figure 3). RASF are activated by inflammatory cytokines and, in response, 
secrete cytokines themselves; these are able to activate immune cells in the synovium to produce even 
more cytokines. At the same time, RASF release chemokines that attract more leukocytes from the 
blood stream. Direct contact of RASF with immune cells further promotes synovial cell activation (19, 
20). Certain soluble mediators produced by RASF such as VEGF or PDGF stimulate synovial 
angiogenesis (46) which, as mentioned earlier, seems to be defective in general and, moreover, facili- 
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Figure 3 Cellular interactions of RASF 
Through the secretion of cytokines and chemokines as well as direct cell-cell contacts (mediated by integrins, 
adhesion molecules and cell surface molecules acting as co-stimulatory factors) RASF recruit and activate 
circulating leukocytes, resident macrophages and promote osteoclast differentiation. Leukocyte extravasation is 
facilitated by increased angiogenesis which is also supported by RASF. In turn, RASF are activated by 
leukocyte- and Mφ-derived products. Abbreviations: EC endothelial cell, Mφ macrophage, CXCL12 chemokine 
(C-X-C motif) ligand 12, IL interleukin, VEGF vascular endothelial growth factor 
 
tates immune cell infiltration because of vessel leakage (37). Activated RASF are a yielding source of 
RANKL and therefore are important promoters of osteoclastogenesis and bone erosions (27, 47). Thus, 
the RASF appears to be at the heart of the events creating an environment of chronic joint 
inflammation, cartilage destruction and bone erosions. 
 
 Cytokine and signalling pathway networks in rheumatoid arthritis 
 
 Cytokine signalling networks are of utmost importance in the development of RA being crucial 
regulators of autoimmunity, chronic synovitis and synovial tissue destruction (48). Articular cells 
express and secrete a great variety of cytokines that activate the secreting cell itself (autocrine) and/or 
other cell types (paracrine) triggering proinflammatory and destructive interactions that ultimately 
perpetuate joint inflammation and destruction (48). TNFα, IL-1β and IL-6 are considered the major 
cytokines involved in RA pathogenesis. Mainly produced by activated macrophages, TNFα influences 
all pathological processes in the RA joint; it causes or supports the production and release of 
proinflammatory cytokines, chemokines, matrix-degrading enzymes and prostaglandins, endothelial 
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cell activation, angiogenesis, leukocyte accumulation and osteoclast activation (49, 50). IL-6 acts on 
leukocyte differentiation and activation, autoantibody production and is the prime inducer of the acute-
phase response; it has been associated with RA-related osteoporosis as well as other systemic 
complications such as cardiovascular disease, fatigue and depression (51). IL-1β promotes synovial 
inflammation and - being an extremely effective inducer of matrix-degrading enzymes and a direct 
activator of bone-resorbing osteoclasts -  is a major driver of tissue destruction; it is estimated that in 
relation to TNFα IL-1β is more important in the destructive processes whereas TNFα is the major 
driver of inflammation (52). Other cytokines that have more recently attracted the attention of the RA 
community are IL-15, IL-17, IL-21, IL-23, and IL-33. Especially, the field of research on the role of 
IL-17 in RA has exploded during the last years and IL-17 was shown to contribute to SF activation, 
osteoclast differentiation, immune cell infiltration, and synovial angiogenesis (53). In different RA 
animal models, IL-17 blockade generated varying responses and three different antibodies targeting 
IL-17 signalling are currently in clinical trials (17, 53). Importantly, the expression of cytokines is 
interdependent; TNFα, for instance, stimulates the expression of IL-6 in SF which in turn activates 
Mφ (the main source of TNFα and IL-1β) and contributes to the development of IL-17-producing 
Th17 cells. Thus, cytokines and the cells they are produced by and act on form a dense network of 
interactions, synergisms and antagonisms that ultimately result in the proinflammatory joint 
environment of RA. 
Of interest, in many cases it seems that blocking one single cytokine (as in the case of TNFα) is 
sufficient to achieve amelioration of inflammation and thereby clinical improvement in RA patients, a 
concept which had been widely rejected when it was initially proposed by Feldmann and Maini in the 
early 1990s (54). Thus, one can assume that cytokine networks become disrupted if one component is 
missing making it easier to target this vicious cycle of proinflammatory actions. Still, a certain 
hierarchy appears to exist as blocking TNFα and IL-6 signalling shows the greatest clinical benefit 
whereas IL-1 blockade has comparably modest effects (17, 55) proving some cytokines “more equal 
than others”1. 
 One cannot look at cytokines without examining the downstream signalling they initiate. Once 
bound to their receptor(s), cytokines activate many different signalling pathways of which the nuclear 
factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), JAK – signal transducer and 
activator of transcription (STAT) and phosphatidylinositol 3-kinase (PI3K) pathways  are considered 
to be among the most important in RA (2). These pathways subsequently activate cell-type specific 
gene transcription programs that eventually contribute to disease pathogenesis. Less well studied 
pathways include the Wingless-type MMTV integration site (Wnt), Notch or mammalian target of 
rapamycin (mTOR) signalling which, nevertheless, take up relevant functions in cartilage and bone 
destruction, inflammation and angiogenesis (56-59).  
                                                 
1 George Orwell, „Animal Farm“ (1945)  
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 In RA, the major pathways activated by TNFα are NF-κB and MAPK signalling (60). The 
sequential phosphorylation of MAPK kinases downstream of TNFα culminates in the activation of 
p38 and Jun kinase (JNK) and the expression of their target genes (60). The JNK-mediated activation 
of the AP-1 transcription factor (via phosphorylation of c-jun) is of particular importance for the 
transcriptional activation of MMPs and therefore joint destruction in RA (61).  
The family of NF-κB proteins comprises five members (p65, c-Rel, RelB, p100/p52 and 
p105/p50) that form homo- or heterodimers binding to κB sites in regulatory sequences of genes (62). 
They are retained in the cytoplasm by Inhibitor of κB (IκB) proteins that mask their nuclear 
localisation sequence. Only upon phosphorylation by the IκB kinase (IKK) complex and the 
subsequent proteasomal degradation of the IκB proteins may NF-κB dimers relocate to the nucleus 
and regulate gene expression (62). Simplified, receptor ligation leads to a series of intracellular events 
involving different adapter proteins, ubiquitin ligases (e.g. the TNF receptor-associated factors 
[TRAFs]) and kinases (e.g. receptor interacting protein 1 [RIP1]) that result in the activation of the 
IKK complex which consists of the catalytic subunits IKK1 and IKK2 and the regulatory subunit NF-
κB essential modulator (NEMO). The canonical pathway (induced among others by TNFα) depends 
on NEMO and IKK2 whereas the noncanonical branch (activated through RANK, for instance) 
requires the NF-κB-inducing kinase (NIK)-mediated phosphorylation of IKK1 (62, 63). The 
importance of TNFα and NF-κB signalling in the pathogenesis of RA is not only exemplified by the 
success of TNF-blocking biologicals in clinical practice (17) but also by the striking phenotype of the 
human TNF transgenic (hTNF tg) mice which spontaneously develop all histological signs of human 
RA (64).  
 Fundamentally, cells and organisms require means of closely controlling and terminating signal 
transduction to prevent a pathological activation of gene expression; in the case of NF-κB signalling 
these include TNFAIP3 (also known as A20), A20-binding inhibitors of NF-κB (ABINs), 
cylindromatosis protein (CYLD) and TRAF1 (63). Whereas TNFAIP3 and CYLD are deubiquitinating 
enzymes disrupting protein-protein interactions TRAF1 most likely inhibits NF-κB signalling through 
its lack of the ubiquitinating activity and competition with the other – NF-κB-activating - TRAF 
proteins (63). TNFAIP3 is of particular interest in RA since a single nucleotide polymorphism (SNP) 
in the TNFAIP3 gene region is associated with RA, as determined by genome-wide association studies 
(65). Furthermore, experimental work convincingly suggests a functional role for TNFAIP3 in RA 
pathogenesis; mice with a knockout of TNFAIP3 specifically in the myeloid lineage develop a 
destructive arthritis (66) and treatment by adenoviral delivery of TNFAIP3 improves clinical signs of 
collagen-induced arthritis (CIA) in mice (67) underlining the important role of NF-κB activity in RA. 
 SF, as mesenchymal cells involved in cartilage turnover, are not a classical source of cytokines. 
In RA, however, they produce high amounts of cytokines and chemokines, especially when stimulated 
with proinflammatory mediators (19, 39) (also see Table 2). One such strong stimulus is TNFα; TNFα 
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stimulation activates NF-κB and MAPK pathways in RASF and leads to the downstream activation of 
matrix-degrading enzymes as well as cytokines and chemokines. These molecules then may further 
contribute to joint inflammation by the attraction (e.g. IL-8, MCP-1, RANTES) and activation of 
immune cells (e.g. IL-6) and, thus, SF are crucial players in the cytokine networks in RA.  
 Taken together, the networks of cytokines and signal transduction pathways among which 
TNFα and NF-κB signalling take up a central position enable synovial cells to communicate and 
coordinate their actions. Together with additional direct cell-cell contacts as well as the intrinsic 
activation of articular cells, in particular the SF, these networks are the basis for the continuing joint 
inflammation and destruction in RA.  
 
2. Epigenetics 
 
The concept of epigenetics was first formulated by developmental biologist Conrad Waddington 
and published in 1957 (68); for him, epigenetics was the study of how developmental decisions are 
reached, i.e. how the genotype gives rise to the phenotype (68, 69). Much later, in the 1990s, this 
perception of epigenetics was considerably changed and defined as the study of heritable alterations in 
gene expression that are not caused by changes in the underlying DNA sequence (i.e. genetics) (69). 
Nowadays, the somewhat expanded definition also includes transient gene expression changes that are 
only in theory heritable and, thus, should rather be understood as “the structural adaptation of 
chromosomal regions so as to register, signal or perpetuate altered activity states” (69). 
As early as 1982, the first abnormally changed epigenetic modification in cancer was described 
showing a loss of DNA methylation in certain genomic regions (70). Since then, a tremendous 
progress has been made in understanding epigenetic regulation in development and disease. Especially 
during the last ten years, the field of epigenetics has experienced a burst. We know now four different 
modifications of DNA and 16 different histone modification classes (summarised in Table 3) (71) that 
are transferred by chromatin “writers” and removed by chromatin “erasers”. These modifications can 
directly change chromatin structure or recruit proteins specifically recognising them, i.e. chromatin 
readers, which themselves bind additional chromatin modifiers and remodelling enzymes. The 
crosstalk of all epigenetic modifications at a genomic locus eventually influences the output of all 
DNA-based processes – DNA replication, repair and transcription (71).  
A recent development in epigenetic research is the acknowledgement of the role of long non-
coding (lnc) RNAs (RNAs more than 200 nt in length) in regulating chromatin structure. Whereas a 
few cis-acting lncRNAs (such as the XIST RNA involved in X chromosome inactivation) have been 
long known the first report of a trans-acting lncRNA was only published in 2007 in Cell (72). High-
throughput genome-wide transcriptomic analyses have revealed the existence of tens of thousands of 
such lncRNAs and it becomes increasingly clear that these may play significant roles as signals, 
decoys, guides and scaffolds in transcriptional and epigenetic regulation (73). Thus, lncRNAs add yet  
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Table 3 Chromatin modifications, readers and their function (from Dawson MA & Kouzarides T (71)) 
 
 
another level of complexity to the epigenetic code which we are - despite all the progress made - only 
beginning to understand. 
 
Histone modifications – a code for accessing the DNA 
 
When outstretched the genomic DNA of a single cell is approximately two metres in length. To 
fit into the nucleus it must be compacted, which at the first level is achieved by the spooling onto 
histones to form the nucleosome, the basic functional unit of chromatin. One nucleosome is made up 
of a histone octamer (one H3:H4 tetramer and two H2A:H2B dimers of the core histones) around 
which 147 bp of DNA are wrapped (1.65 turns). The linker histone H1 binds to the nucleosome-free 
region between two neighbouring nucleosomes (20-50bp of linker DNA) and functions as a kind of 
molecular glue fixing the nucleosome position (74). Posttranslational modifications (PTMs) of 
histones occur mostly at the N-terminal tails protruding from the nucleosome and the most thoroughly 
studied modifications are acetylation, methylation and phosphorylation (Figure 4).  
Nε-acetylation of lysine (K) residues (transferred by histone acetyltransferases – KATs – and 
removed by histone deacetylases – HDACs) is universally connected with gene activation being wide- 
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Figure 4 The nucleosome (from Dawson MA, Kouzarides T and Huntley BJP (75)) 
A. DNA is wrapped around the histone octamer consisting of two each of the four different core histones H2A, 
H2B, H3 and H4. B. Posttranslational modifications of the histone tails include but are not limited to methylation 
(Me), acetylation (Ac), phosphorylation (Ph) and ubiquitination (Ub). 
 
ly found at promoters, enhancers and sometimes even throughout the whole region of actively 
transcribed genes (71). Neutralisation of the positively charged ε-amino group by acetylation loosens 
the interaction with the negatively charged sugar phosphate backbone of the DNA and, thus, histone 
acetylation-marked chromatin is considered to have a more “open” conformation facilitating the 
access of the transcriptional machinery. Additionally, histone acetylation is recognised by chromatin 
readers of the bromodomain and plant homeodomain (PHD) classes that effect epigenetic regulation or 
may recruit further epigenetic effectors (75). 
Histone methylation occurs at lysine, arginine and (though less well understood) histidine 
residues; lysines are symmetrically mono-, di- and trimethylated at their ε-amino group while 
arginines are mono- or dimethylated (symmetrically or non-symmetrically) at their guanidino group. 
In contrast to (de)acetylases, the enzymes that write and erase histone methylation act in a site-specific 
manner. The best studied histone methylation marks are those at lysine side chains which are 
transferred by SET domain-containing histone methyltransferases (KMT) (with one exception) and 
removed by histone demethylases of the LSD1 or Jumonji family classes (71). Site-specific histone 
lysine methylation is connected to distinct transcriptional outputs; in this regard, histone 3 lysine 4 
(H3K4), H3K36 and H3K79 methylation are associated with euchromatic regions of active gene 
transcription whereas H3K9, H3K27 and H4K20 methylation are found in transcriptionally silent, 
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heterochromatic regions (71, 74). Interestingly, H3K4 and H3K27 methylation may simultaneously be 
present in bivalent domains, especially in developmental genes, allowing for rapid gene activation or 
deactivation during development (76, 77). Methylation does not change the charge of amino acid 
residues within the histone tails and, thus, the mode of action of this modification depends on 
chromatin readers. Proteins with binding domains of the PHD finger and Royal Family (chromo, 
malignant brain tumour and tudor domain) then further execute the command of gene silencing or 
activation (71, 75). 
Kinases, usually with already established roles in cell signalling such as JAK2, ATM and PIM1, 
can phosphorylate histone serines, threonines and tyrosines. By altering the charge of the histone, 
phosphorylation influences transcriptional regulation and chromatin condensation (71). Currently, 
there is not much knowledge about histone phosphatases although the very dynamic nature of histone 
phosphorylation clearly argues for their existence and importance (71). 
Of interest, histone-modifying enzymes can additionally have non-histone protein targets (e.g. 
p53) whose activity they modulate which, when studying these enzymes, may cause problems in 
dissecting which of the effects seen are truly epigenetic in nature (71). 
In conclusion, a picture emerges in which all histone modifications in combination regulate 
gene transcription, DNA repair and replication. Some modifications may act synergistically, some are 
mutually exclusive and yet others set chromatin into a state poised for further activation or silencing. 
This combinatorial action of the histone PTMs has been termed the “histone code” (78). 
 
DNA methylation – marking DNA for transcriptional repression 
 
DNA methylation, the methylation of cytosine residues at the fifth carbon atom of the 
pyrimidine ring (5mC), results in the repression of gene transcription. It almost exclusively occurs in 
the context of CpG dinucleotides within CpG islands (stretches of DNA longer than 200 bp and 
enriched for CpGs) which are present in ~70% of all promoter regions (71). These, however, are 
generally unmethylated and only acquire methylation during development and disease in a tissue-
specific fashion (74). 5mC can directly inhibit transcription by preventing the binding of 
transcriptional activators or by the recruitment of methyl-CpG-binding domain (MBD) proteins that 
subsequently guide histone modifiers and chromatin remodellers towards the DNA (74). Recent 
genome-wide sequencing platforms have identified alterations in the methylation of CpG shores, 
regions less proximal to the promoter with a lower CpG density than CpG islands; for the moment, 
however, their role remains insufficiently understood (74, 79). 
DNA methylation is carried out by the family of DNA methyltransferases (DNMTs). DNMT1 is 
the maintenance DNMT that re-establishes complete methylation at hemimethylated DNA during 
replication. The de novo DNMTs 3A and 3B establish new patterns of DNA methylation particularly 
during embryogenesis. A final prove for active DNA demethylation has not been found, yet. It is 
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assumed that the other covalent DNA modifications - 5-hydroxymethylcytosine, 5-formylcytosine and 
5-carboxylcytosine (cf. Table 3) – are intermediates of a step-wise oxidation by TET family 5-
methylcytosine hydroxylases which eventually results in DNA demethylation (71). The existence of 
bona fide DNA demethylases is still an open question. 
 
Chromatin remodelling – rolling the nucleosomes 
 
The position of the nucleosomes on the DNA governs the accessibility of the transcription start 
site. Therefore, chromatin readers associate with the macromolecular machines of chromatin 
remodellers that move, destabilise, eject and restructure nucleosomes to enable or prevent transcription 
initiation, a process which is strictly ATP-dependent (74). In mammals, four families of chromatin 
remodelling complexes with different activities, functions and domain structures are known: the 
switching defective/sucrose nonfermenting (SWI/SNF), the imitation SWI (ISWI), the nucleosome 
remodelling and deacetylation (NuRD)/Mi-2/chromodomain helicase DNA-binding (CHD), and the 
inositol requiring 80 (INO80) families (71). The exact mode of how nucleosomes are positioned is not 
clear yet but it seems that the DNA sequence itself (i.e. preferred or disfavoured DNA motifs), DNA 
methylation, histone modifications and histone variants guide this process (80). Histone variants may 
greatly (e.g. H2A.Z, centromere protein A [CENP-A]) or only slightly (e.g. H3.3) deviate from 
canonical histones at the level of their amino acid sequence or domain structure. They display a 
specific spatial and/or temporal pattern of incorporation into the chromatin and thereby take influence 
on certain biological processes such as DNA replication (CENP-A instead of H3) or DNA repair 
(H2A.X) (80). 
 
Epigenetics in disease – the cellular memory out of control 
 
The collectivity of all epigenetic modifications (their presence as well as their absence) – the 
“epigenetic landscape” – controls the assembly of functional complexes impacting on all DNA-based 
processes. Not surprisingly, disruption of this tightly regulated system results in developmental defects 
and diseases. Aberrant epigenetic regulation has been found in multiple human diseases, first of all in 
cancer but also in neurodevelopmental disorders, neurodegenerative and neurological diseases, and 
autoimmune diseases (74).  
Pathological epigenetics are mostly studied in the field of cancer research. Erroneous 
overexpression or silencing of epigenetic regulators causes significant changes in the epigenetic 
profiles of affected cells and thereby gene expression patterns are disturbed. In cancer, one generally 
finds global hypomethylation of DNA with hypermethylation at specific genomic loci, in particular 
promoter CpGs that should normally be unmethylated (79). This leads to the unwanted silencing of 
tumour suppressor genes which abets malignant transformation. Other promoters become 
Chapter I – Introduction 
 - 19 -  
hypomethylated which enables the expression of oncogenes. Furthermore, global DNA 
hypomethylation is associated with the re-activation of transposable elements such as LINE1 which 
results in chromosomal instability (74). The global profile of histone modifications in cancer cells is 
skewed towards reduced acetylation, loss of the permissive H3K4me3 and the repressive H4K20me3 
as well as increases in the repressive H3K9me3 and H3K27me3 marks (74). 
In autoimmune rheumatic diseases, epigenetic changes have mainly been studied in systemic 
lupus erythematosus (SLE) and RA. DNA in T cells from SLE patients, for instance, is globally 
hypomethylated and several T cell function-related genes were shown to be overexpressed as a result 
(e.g. CD70, CD40 ligand and perforin 1) (81). 
Recently it has become clear that not only the expression of epigenetic enzymes may be 
dysregulated but that genomic translocations and coding mutations of epigenetic regulators can form 
the basis of some diseases through a combination of genetic and epigenetic factors (79). One such 
example is the histone methyltransferase Enhancer of Zeste homologue 2 (EZH2): several gain-of-
function mutations of this enzyme have been found in lymphomas that change the activity of EZH2 
and, thus, may influence histone methylation patterns (82, 83). EZH2 was among the first epigenetic 
enzymes to be found overexpressed in a variety of malignant diseases; by its methylating activity on 
H3K27 EZH2 silences tumour suppressor genes (84). For this reason it has been considered as a bona 
fide oncogene for a long time. New data revealing a possible tumour suppressive function of EZH2 in 
certain haematologic malignancies have recently questioned this notion and further work is necessary 
to enlighten the ambiguous role of EZH2 in tumour biology (71, 85). Nevertheless, in all solid tumours 
studied EZH2 has been found overexpressed. EZH2 is a crucial regulator of developmental genes such 
as its primordial target, the homeobox transcription factor (HOX) gene family, and others of the 
Notch, Wnt and Hedgehog signalling pathways (86, 87). Interestingly these pathways are also 
implicated in the pathogenesis of RA.   
The therapeutic interference with pathological epigenetic changes is a fascinating concept 
currently pursued by several investigators at various preclinical and clinical stages (71). Whereas 
inhibitors for enzymes modifying histone methylation (e.g. EZH2) and bromodomain chromatin 
readers are only in development in pre-clinical stages some epigenetic therapies have already received 
approval by the US Food and Drug Administration (FDA) (71). The hypomethylating agents 
azacitidine and decitabine, inhibitors of DNMTs, are in clinical use for myelodisplastic syndrome. 
Vorinostat and romidepsin are both pan-HDAC inhibitors showing great efficacy in patients with 
cutaneous T cell lymphoma (71, 79). New approaches in this field will be the combination of different 
epigenetic drugs to improve efficacy and reduce unwanted effects. Furthermore, it has been suggested 
to use epigenetic drugs in conjunction with conventional chemotherapy to better manage resistance to 
cancer therapy (79). In summary, this field holds excellent promise for the future improvement and 
replacement of current therapies to the benefit of the patient.  
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Rheumatoid arthritis – inflammatory epigenetics (?) 
 
The first report of an aberrant epigenetic modification in RA goes back to the year 1990: Bruce 
Richardson and colleagues detected impaired DNA methylation in T cells from RA patients (88). Later 
it was found that MTX treatment could reverse this global loss of DNA methylation in peripheral 
blood mononuclear cells (PBMCs) (89). Detailed molecular studies into the pathogenetic function of 
DNA hypomethylation in RA, however, were not undertaken until the new millennium. 
With respect to the fact that RA synovial cells appear to be defective in apoptosis Takami et al. 
demonstrated high DNA methylation levels in the promoter CpG island of the apoptosis-mediating 
receptor DR3 gene compared with control OA synovial cells (90). RA peripheral blood lymphocytes 
presented with a loss of DNA methylation in the promoter region of the EFNB1 gene and the 
associated overexpression of Ephrin B1 was connected to increased migration and cytokine production 
in these cells (91). Further studies identified DNA methylation defects in the promoter of IL6 in RA 
PBMCs (loss of methylation at a single CpG site with concomitant IL6 upregulation (92)), the 
promoter of FOXP3 in RA CD4+ T cells (hypermethylation albeit without accompanying gene 
expression change (93)) and the X-linked CD40L promoter in female RA CD4+ T cells (94). These 
data strongly argue for a pathogenetic role of DNA methylation in RA. 
Epigenetic dysregulation represents an attractive and very likely explanation for the activated 
phenotype of RASF. In 2009, Karouzakis and co-authors demonstrated global DNA hypomethylation 
in RA synovial tissue and in RASF compared with OA samples alongside reduced DNMT1 levels in 
proliferating SF (95). Bisulfite sequencing revealed hypomethylation of the LINE1 transposon which 
is re-activated in RA. In vitro-hypomethylation of normal SF with 5-azacytidine upregulated the 
expression of genes involved in the pathogenesis of RA such as interleukins, adhesion molecules and 
matrix-degrading enzymes. These data suggested that the intrinsically activated phenotype of RASF is 
caused  by epigenetic dysregulation, in particular by genomic hypomethylation (95). Follow-up 
projects identified reduced DNA methylation at the CXCL12 gene and a concomitant overexpression 
of the CXCL12 chemokine in RASF (96) as well as reduced levels of the methyl donor S-adenosyl 
methionine (SAM). The latter finding was explained by the increased recycling of polyamines in 
RASF posing the possibility of global hypomethylation being, at least in part, due to the consumption 
of SAM by this pathway (97). Studying the methylome of RASF and OASF, 1859 differentially 
methylated loci were recently identified many of which were connected to genes involved in joint 
architecture and inflammation, for instance integrins and signal transduction pathway components 
(e.g. STAT3) (98). 
Despite the relative wealth of information on DNA methylation detailed analyses of other 
epigenetic modifications in RA are rather scarce. Most studies have concentrated on the use of HDAC 
inhibitors (HDACi) in preclinical models of the disease and the expression pattern of histone 
acetylation-modifying enzymes is still a matter of controversy. Huber et al. reported the HDAC/KAT 
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activity ratio to be decreased in RA synovial tissue together with reduced protein levels of HDAC1 
and 2 (99). This was later contradicted by a study from Kawabata and co-workers; they found 
increased HDAC activity and increased HDAC1 expression in RA synovial tissue (100). It was 
speculated that this discrepancy may have arisen from differences in therapy and the method of 
acquisition of the biological material (45, 100). Either way, more research is necessary to conclusively 
clarify this question. Looking at class III HDACs (sirtuins), SIRT1 was found to be overexpressed in 
RA synovial tissue, RASF and RA blood monocytes and to mediate apoptosis resistance in RASF as 
well as IL-6 and TNFα secretion from RASF and monocytes, respectively (101). 
Experiments using various HDACi generally showed beneficial effects in RA animal models 
and in in vitro assays (reviewed in 102). Different HDACi, for instance, suppressed cytokine 
production and induced apoptosis in peripheral blood and synovial fluid Mφ, and inhibited the 
production of cytokines from synovial tissue explant cultures (103). RA PBMCs, which displayed 
increased HDAC activity compared to healthy control PBMCs, were inhibited to secrete IL-6 by a no- 
 
Figure 5 Epigenetic changes in RA 
In RA, global as well as promoter DNA methylation and histone acetylation have been studied in peripheral 
blood leukoocytes (left), synovial tissue and synovial cells, in particular SF (right). Together, these epigenetic 
aberrations contribute to immune cell activation and migration, and SF activation ultimately favouring a synovial 
environment of chronic inflammation, hyperplasia and tissue destruction. Abbreviations: PBL peripheral blood 
lymphocytes, SIRT1 silent mating type information regulation 2 homologue (sirtuin) 1, HDAC histone 
deacetylase, Act activity, 5mC 5-methylcytosine, Ac histone acetylation, DNMT1 DNA methyltransferase 1, 
EFNB1 ephrin B1, IL6 interleukin 6, CD40L cluster of differentiation 40 ligand, L1 LINE1 retrotransposable 
element, ITGA4 integrin alpha 4, STAT3 signal transducer and activator of transcription 3, CXCL12 chemokine 
(C-X-C motif) ligand 12, MMP1 matrix metalloprotease 1, TIMP2 tissue inhibitor of metalloproteases 2, DR3 
death receptor 3. 
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vel HDAC3-specific HDACi (104). HDACi studies, however, only give indirect evidence of 
epigenetic changes in RA. Considering the many non-histone protein targets of histone modifying 
enzymes the effects observed using HDCAi may after all not be related to epigenetic mechanisms. In 
line with this, Grabiec et al. demonstrated that HDACi-mediated IL6 repression in RASF was not due 
to epigenetic regulation but due to changes in NF-κB activity and IL6 mRNA stability (105). 
Using chromatin immunoprecipitation Maciejewska-Rodrigues and co-workers were able to 
show increased H4 acetylation levels at the MMP1 promoter in RASF as compared to OASF which 
may lead to the upregulation of MMP1 in RASF (106). Another study implicates increased H3 
acetylation at the IL17 promoter in synovial Th17 differentiation (107).  
In summary, several lines of evidence point towards the involvement of epigenetic 
dysregulation in the pathogenesis of RA (Figure 5). Still, there is a vast knowledge gap to bridge until 
the epigenetics of the rheumatoid joint are understood. In particular, the exact effects of HDACi on 
histone and non-histone targets must be distinguished and histone modifications other than histone 
acetylation have not been addressed at all so far. 
 
3. microRNAs 
 
Tiny finetuners of gene expression under strict control 
 
microRNAs (miRNAs) are approximately 22nt-short non-coding RNAs that regulate the 
expression of protein-coding genes at the posttranscriptional level by degradation and/or inhibiting 
translation of the target mRNA. The first miRNA (lin-4) was discovered in 1993 in the nematode 
Caenorhabditis elegans providing the first explanation how the non-coding lin-4 gene product could 
repress the expression of the LIN-14 protein without obvious changes in the expression of the 
corresponding mRNA (108). 
Since the discovery of the founding member lin-4, thousands of other, generally evolutionarily 
conserved, miRNAs have been found across the whole metazoan kingdom as well as in plants. Plant 
and animal miRNAs, however, differ in several aspects of their biogenesis and mode of action 
implying independent evolution of miRNA pathways in the two kingdoms (108). The broad 
conservation of miRNAs and miRNA pathways within Animalia and Plantae, nevertheless, argues for 
the importance of this class of gene expression regulators. 
Small non-coding RNAs such as transfer RNAs (tRNAs) and small nuclear RNAs (snRNAs) are 
essential components of the cellular translation and splicing machineries and are, as such, transcribed 
as housekeeping genes from RNA polymerase III promoters. In contrast, miRNAs are just as protein-
coding genes transcribed by RNA polymerase II and, thus, miRNA expression is subject to similar 
mechanisms of gene regulation (109). miRNAs are encoded by independent genes or may be derived 
from introns of mRNAs after the splicing of the primary transcript. In the canonical miRNA biogene- 
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Figure 6 microRNA biogenesis (adapted from Krol J, Loedige I and Filipowicz W (109)) 
MicroRNA genes are transcribed by RNA polymerase II, processed by the RNase III enzyme Drosha or 
alternatively the spliceosome (mirtrons), exported from the nucleus by Exportin 5 and cleaved by a second class 
III-RNase, Dicer. The mature miRNA guide strand is loaded onto the miRNA-induced silencing complex 
(miRISC) and executes miRNA functions while the passenger strand is (usually) degraded. Abbreviations: 
RNAPII RNA polymerase II, DGCR8 DiGeorge syndrome critical region 8, pri-miRNA primary miRNA, pre-
miRNA precursor miRNA, m7G 5’7-methylguanosine cap, AGO2 argonaute 2, ac-pre-miRNA AGO2-cleaved 
pre-miRNA, TRBP transactivation-responsive RNA-binding protein, GW182 glycine-tryptophan protein of 182 
kDa, PABP poly(A)-binding protein, CCR4 CC chemokine receptor type 4, CAF1 CCR4-associated factor 1  
  
sis pathway (Figure 6), these primary transcripts (pri-miRNA) fold into hairpin structures that are 
recognised by the microprocessor complex whose core components are the RNA-binding protein 
(RBP) DiGeorge syndrome critical region 8 (DGCR8) and the RNase III enzyme Drosha (109, 110). 
The microprocessor cleaves the hairpin at its base to release the ~70nt precursor- (pre)-miRNA which 
is bound by Exportin 5-Ran and is actively transported to the cytoplasm with the help of Ran-mediated 
GTP hydrolysis. There the hairpin is cleaved off by the RNase III Dicer to yield an unstable duplex of 
the mature miRNA guide strand and passenger strand (miRNA*) with 2nt of 3’ overhang in both 
strands. The transactivation-responsive RBP (TRBP) supports the Dicer-mediated pre-miRNA 
cleavage and then ensures the loading of the guide strand into an argonaute (Ago) protein and 
assembly of the miRNA-induced silencing complex (miRISC) (110). Selection of guide and passenger 
strand is dependent on the thermodynamic stability of the miRNA/miRNA* duplex and the passenger 
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strand normally is degraded (109). Recently, however, evidence for stable expression and biological 
functions of miRNA* species has been accumulating (109).  
Alternative pathways for the biogenesis of miRNAs include the mirtron pathway (Figure 6), 
small nucleolar (sno) RNA-derived miRNAs, tRNAse Z-derived miRNAs and the special case of 
Dicer-independent miR-451 biogenesis (111). Mirtons are very short introns in which the spliceosome 
substitutes for the necessity of the microprocessor complex. After debranching of the resulting lariat 
structure the mirtron product resembles a pre-miRNA and further proceeds through the canonical 
pathway (111). pri-miR-451, in contrast, initially goes through the canonical steps of Drosha-mediated 
cleavage and export from the nucleus. But pre-miR-451 cannot be cut by Dicer and instead may be 
loaded onto Ago2 where it is sliced to yield the Ago2-cleaved (ac-)pre-miR-451 which is further 
processed to become the mature miR-451 by a nuclease yet to be identified (111). 
miRNA biogenesis is tightly controlled at basically every level of the pathway to ensure correct 
spatiotemporal miRNA expression (109, 112). Being RNA polymerase II-dependent, pri-miRNA 
transcription is under the control of transcription factors and regulatory elements as well as epigenetic 
mechanisms. Therefore, miRNA promoters closely resemble the promoters of protein-coding genes 
and, similarly, their activity is regulated in a tissue-, development- and stimulation-dependent manner 
(109, 112). The further processing steps are greatly influenced by RBPs and other accessory proteins. 
Cellular total levels of Drosha, DGCR8 and Dicer as well as the activity of these components are 
rigorously regulated. The DEAD box helicases p68 (DDX5) and p72 (DDX17), for instance, are 
essential elements of the microprocessor and knockout of either one causes embryonic lethality in 
mice (112). Another example is the alternative splicing factor heterogeneous nuclear ribonucleoprotein 
(hnRNP) A1 which was shown to enhance pre-miR-18a maturation without influencing the other 
miRNAs derived from the polycistronic miR-17-92 cluster (encoding miR-18a and five other 
miRNAs). Other levels of regulation may be RNA editing by adenosine deaminases that act on RNA 
(ADARs) which influences the processing and the control of nuclear export of the pre-miRNA (109, 
112). All these means of regulating miRNA biogenesis may be carried out in a cell type-, stimulation-, 
tissue-dependent fashion and are in part miRNA-specific; therefore, they may account for differences 
observed in individual miRNA levels (109, 110). 
miRNAs bind their target mRNAs through perfect complementarity (especially in plants) or, 
much more often, partial complementarity with the 3’ untranslated region (UTR). The binding part of 
the miRNA is called the seed region and generally constitutes nucleotides 2 to 7 (or 8) at the 5’ end of 
the mature miRNA (Figure 7A, B). Since binding specificity is determined by only six or seven 
nucleotides it is not surprising that one miRNA can have several hundreds of targets. At the same 
time, one mRNA may be the target of multiple miRNAs. Computational prediction programmes avail 
of the sequence-specific nature of miRNA-mRNA interactions to predict potential miRNA target 
genes which substantially eases the search for biological functions of miRNAs. Nevertheless, these 
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algorithms produce a high proportion of false positive predictions while missing out other targets so 
that direct miRNA-target interactions still need to be verified for each pair individually (113, 114). 
Upon maturation miRNAs are incorporated into the miRISC complex which is facilitated by the 
interaction of Dicer with several other proteins forming the RISC loading complex (112). The major 
components of miRISC are one of the four Ago proteins and the glycine-tryptophan repeat-containing 
protein of 182 kDa (GW182). The exact mode of action of the miRISC has not been elucidated so far 
but it appears that miRISC inhibits translation initiation and possibly elongation and mediates mRNA 
deadenylation, decapping and degradation (115) (Figure 7C). In eukaryotes, translation starts with the 
recruitment of the translation initiation factor eIF4F to the 5’cap of the mRNA and the subsequent 
assembly of the 43S pre-initiation complex (consisting of the 40S small subunit of the ribosome, the 
initiator tRNA and a couple of initiation factors) (116). This complex then starts scanning the mRNA 
in 5’→3’ direction and upon base pairing of the anti-codon with the start codon all initiation factors 
 
 
Figure 7 Mechanisms of miRNA-mediated gene repression 
A. Sequence of a mature miRNA (miR-18a) with the seed sequence in dark red. B. Structure of a typical mRNA 
consisting of the 5’ untranslated region (UTR) (dark green) with the 5’cap, coding sequence (dark blue) and 
3’UTR (orange) with the poly(A) tail. miRNA binding sites (the sequence reverse complementary to the seed 
sequence = seed match, dark red) usually lie in the 3’UTR. C. Upon miRISC assembly at the target mRNA the 
GW182-mediated protein-protein interactions inhibit mRNA circularisation and binding of the translation 
initiation factor eIF4F to the 5’cap thereby preventing 40S ribosomal subunit recruitment. GW182 recruits two 
deadenylase complexes, CCR4-NOT1 and PAN2-PAN3. Removal of the poly(A) tail favours the decapping of 
the mRNA (DCP1-DCP2 complex) and the subsequent 5’→3’-exonucleolytic breakdown of the mRNA (Xrn1). 
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are released and the large 60S ribosomal subunit is allowed to bind. Of importance, to increase the 
efficiency of translation, mRNAs are circularised by an interaction of the 5’cap binder eIF4F and the 
poly(A) binding protein (PABP) thereby placing the ribosome in an ideal position to re-initiate 
translation after a cycle has been finished (116). The miRISC is believed to prevent binding of the 5’ 
cap of the mRNA by eIF4E (a subunit of eIF4F) thereby impeding ribosome assembly and the 
interaction of GW182 with the PABP might interfere with mRNA circularisation (115). As to miRNA-
mediated mRNA decay, GW182 was shown to bind two deadenylase complexes, the CC chemokine 
receptor type 4 – negative regulator of transcription (CCR4-NOT) and the poly(A)-specific 
ribonuclease 2 & 3 (PAN2-PAN3) deadenylation complexes. In eukaryotes, removal of the poly(A) 
tails destabilises the mRNA and so, subsequently, the 5’cap of the mRNA is removed by a decapping 
enzyme complex (DCP1-DCP2), and the mRNA finally is broken down by the 5’-3’ exoribonuclease 
1 (Xrn1) (115). The relative proportion of translation inhibition and mRNA degradation in miRNA-
mediated gene repression remains one of the most important issues that have not yet been entirely 
illuminated. Recent studies point towards a sequential model in which inhibition of translation 
precedes mRNA degradation and that the block in translation possibly favours deadenylation and the 
subsequent mRNA decay (115, 117). This model also allows for the possibility that gene repression 
takes place only at the protein level, i.e. it does not proceed through all silencing steps, e.g. to achieve 
better reversibility of the silencing (117). 
Target recognition and accessibility is another tightly regulated level of the miRNA pathway. 
An array of RBPs binding to 3’UTRs can counteract or facilitate the miRNA-target interaction. The 
AU-rich element-binding Hu proteins are stabilisers of mRNAs; in this regard, the ubiquitously 
expressed HuR protein was shown to relieve miR-122-mediated repression of cationic amino acid 
transporter 1 mRNA by binding to its 3’UTR (110, 115). A hnRNP family member, hnRNPL, may 
prevent miRNA binding to the VEGFA mRNA during hypoxia and another RBP, dead end 1, rescues 
the cyclin-dependent kinase inhibitor 1B (CDKN1B, p27) from repression by direct interference with 
miRNA binding sites (110, 115). The PUF RNA binding protein Pumilio 1 (Pum1), in contrast, enables 
the binding of miR-221 and miR-222 to the CDKN1B mRNA upon growth factor stimulation by 
changing the secondary 3’UTR structure making it more accessible (110, 115). A new fascinating 
mechanism of controlling miRNA activity, and thus target binding, has recently emerged with the 
discovery of competing endogenous RNAs (ceRNAs), a class of lncRNA also termed natural miRNA 
sponges (118). Without having another obvious function these ceRNAs act as decoys for miRNAs 
thereby preventing miRNA binding to other target RNAs. A prime example is the PTEN pseudogene 
PTENP1 which harbours several miRNA binding sites in the 5’ region of its “3’UTR” that is highly 
similar to the PTEN 3’UTR. Therefore, PTENP1 acts as a tumour suppressor by intercepting miRNAs 
that are otherwise bound to repress the PTEN mRNA (119).  
In some cells, also the subcellular localisation of miRNAs is under deliberate control, a 
mechanism that has been shown to be exceptionally important in nerve cells where miRNA and, thus, 
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target expression in the cell body and dendrites can differ substantially (109). The last instance of 
miRNA regulation is the stability of the miRNA itself. In general, miRNAs are highly stable 
molecules with half-lives of several hours or even days but under certain circumstances miRNA 
turnover needs to be speeded up and regulated miRNA decay has been found in multiple cell types and 
for various miRNAs (109). 
In summary, miRNA biogenesis and action represent a highly concerted pathway whose 
detailed mechanisms are becoming gradually clear. Disruption of this pathway can have detrimental 
effects and dysregulated expression of miRNAs or miRNA pathway components is found in many 
human pathologies. As with epigenetics, miRNA dysregulation is most extensively studied in cancer 
research and numerous cancer-associated miRNAs (“oncomirs”) have been identified. Moreover,  
miRNAs play significant roles in various other processes such as angiogenesis, haematopoiesis, 
vascular remodelling, cardiac hypertrophy, and myogenesis and, as a result, have been implicated in 
the pathogenesis of many diseases (120). Importantly, also biological samples from patients with 
autoimmune diseases such as SLE and RA display aberrant miRNA expression profiles and 
consequential functional abnormalities.  
 
Micro-regulation of rheumatoid arthritis 
 
The first paper to connect RA with the miRNA pathway did not deal with the expression of 
miRNAs but with autoantibodies to GW bodies (cytoplasmic foci to which the miRNA silencing 
machinery locates) in the sera of patients of different medical conditions (121). This study, however, 
included only three RA patients and all three had additional other diagnoses. The impact of this 
interesting but somewhat anecdotic finding on the pathogenesis of RA must therefore be questioned 
for the moment.  
Nevertheless, intensive research over the last five years has produced a first comprehensive list 
of miRNAs dysregulated in RA (Table 4). The first study reporting miRNA differential expression in 
RA came from Stanczyk and colleagues (122). They showed upregulation of miR-155 in RASF and 
RA synovial tissue compared to OA samples. Additionally, miR-146a was found to be increased in 
RASF. Enforced expression of miR-155 in RASF reduced the expression of MMP1 and 3 and, thus, 
miR-155 upregulation was suggested to be a protective mechanism that counter regulates tissue 
destruction (122). Other miRNAs identified to be upregulated in RASF were miR-223, miR-142-5p 
and -3p, miR-133a (123), miR-221/222, miR-323 (124) and miR-203 (125) whereas miR-124a (123) 
and miR-34a* (126) were reduced. Individual miRNA expression differences were also found in whole 
synovial tissue and peripheral blood cells (see Table 4). Apart from evaluating human biological 
material some papers reported on the expression of miRNAs in animal models of RA. Thus, miR-155 
(127) and miR-146a were shown to be increased in the articular tissue of mice with CIA whereas the 
expression of miR-23b was reduced (128). Paradoxically, intravenous injection of miR-146a inhibited 
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Table 4 Differential expression of miRNAs in human RA 
 
miRNA change  
cell type/biological 
sample#  
function/effect of miRNA expression 
change  
miRNA 
target## 
       miR-16 ↑ 
 
PBMCs (129) 
synovial fluid (130)  
 
 
miR-124a ↓ 
 
RASF (123)  
RASF proliferation ↑, MCP-1 and 
Angiogenin release ↑ (123)  
CDK2 
MCP1 
(ANG) 
miR-132 ↑ 
 
PBMCs (129)  
 
 
 
miR-132 ↓ 
 
plasma (130)  
 
 
 
miR-133a ↑ 
 
RASF (123)  
 
 
 
miR-142-5p ↑ 
 
RASF (123)  
 
 
 
miR-142-3p ↑ 
 
RASF (123)  
 
  
miR-146a ↑ 
 
RASF (122, 123) 
CD4+ T cells (131) 
synovial tissue (128, 132) 
PBMCs (129) 
synovial fluid (130) 
 
T cell apoptosis ↓ (131) 
 
  
(FAF1) 
 
 
miR-155 ↑ 
 
RASF (122, 124) 
synovial tissue (122) 
PBMCs (129) 
synovial fluid (130) 
synovial Mφ (127) 
 
MMP1 and MMP3 expression in 
RASF ↓(122) 
Mo secretion of TNFα, IL-6, IL-8, 
IL-1β ↑, of IL-10 ↓ (127)  
 
 
SHIP1 
miR-203 ↑ 
 
RASF (125)  
MMP1 and IL6 expression in 
RASF ↑ (125)  
 
miR-221/222 ↑ 
 
RASF (124)    
 
miR-23b ↓ 
 
synovial tissue (128)  increased NF-κB signalling (128)  
TAB3 
IKKα 
TAB2 
miR-223 ↑ 
 
RASF (123) 
T cells (133) 
synovial fluid (130) 
synovial tissue (134) 
 
 
 
inhibits in vitro osteoclastogenesis 
(134) 
 
 
miR-323 ↑ 
 
RASF (124)  
increased Wnt signalling (124) 
 
(BTRC) 
miR-34a* ↓   RASF (126)   RASF apoptosis resistance (126)   XIAP 
#RA sample compared to OA or healthy control, ##new miRNA targets identified, for genes in parentheses no 
direct miRNA-target interaction proven. CDK2 = cyclin-dependent kinase 2, MCP1 = monocyte chemoattractant 
protein 1, FAF1 = Fas-associated factor 1, SHIP1 = Src homology 2-containing phosphatase 1, TAB = TGF-β-
activated kinase 1/MAP3K7 binding protein, IKKα = Inhibitor of κB kinase a, BTRC = β-transducin repeat 
containing, XIAP = X-linked inhibitor of apoptosis 
 
bone destruction in the CIA model, an effect that was explained by the fact that TRAF6 and 
interleukin-1 receptor-associated kinase 1 (IRAK1), components of the NF-κB signalling cascade 
which is crucial for osteoclastogenesis, are direct targets of miR-146a (135). Analysing SF derived 
from the hTNF tg mouse model of arthritis, Pandis and co-workers found several differentially 
expressed miRNAs some of which were similarly dysregulated in human RASF (miR-155, miR-
221/222, miR-323) (124). It is remarkable that miR-146a and miR-155 are overexpressed in every 
biological sample studied so far in the context of RA. Considering their important role in regulating 
immune function and inflammation (136, 137), however, this is not very surprising. miR-155, for 
instance, is critically involved in B cell maturation and B and T cell function and some of the validated 
targets include IKKε, suppressor of cytokine signalling 1 (SOCS1), and receptor-interacting 
Chapter I – Introduction 
 - 29 -  
serine/threonine kinase 1 (RIPK1), all of them elements of inflammatory signalling pathways (136, 
138). Beside IRAK1 and TRAF6, miR-146a was further demonstrated to target for example IRAK2, 
IL-8, Fas-associated via death domain (FADD), and Rho-associated coiled-coil containing protein 
kinase 1 (ROCK1) thereby affecting the innate and the adaptive immune response, cell survival and 
invasion (137). 
With respect to miR-146a and its target IRAK1, Chatzikyriakidou et al. studied SNPs in both 
genes in the context of RA (139). Whereas the miR-146a variant did not predispose to develop RA one 
of the SNPs in the 3’UTR of IRAK1 was connected with susceptibility to RA (139). But since that 
SNP does not overlap with the miR-146a seed matches it remains to be determined which biological 
function it has and whether it might influence miRNA binding to the IRAK1 mRNA. Nevertheless, 
this study should arguably inspire more comprehensive analyses of disease pathology-relevant SNPs 
and their potential to interfere with the miRNA pathway.     
Although the interest in measuring miRNA expression has been high in recent years studies 
associating miRNA dysregulation with an actual biological function and identifying new miRNA 
target genes relevant to the pathogenesis of RA have been rare. The most notable papers in this regard 
were published by Kurowska-Stolarska et al. in 2011 (127) and by Zhu and co-workers in 2012 (128). 
Src homology 2-containing inositol phosphatase-1 (SHIP1), an inhibitor of inflammatory signalling 
pathways, was identified as a direct target of miR-155 and to be downregulated in RA synovial tissue 
Mφ (127). miR-155 knockout mice were protected against CIA as evidenced by lack of synovial 
inflammation and cartilage and bone destruction and this went along with increased expression of 
SHIP1 in bone marrow-derived Mφ (127). A simultaneously published paper supports the data of miR-
155-/--protection from CIA and shows that, in contrast to CIA, miR-155 knockout does not influence 
the development of K/BxN serum transfer arthritis although it could inhibit osteoclastogenesis (140). 
Zhu et al. found miR-23b to directly repress several genes involved in inflammatory signalling 
pathways, namely TGF-β-activated kinase 1/MAP3K7 binding protein (TAB) 2 and 3 and IKKα 
(128). Concomitant with reduced expression of miR-23b in RA synovial tissue the three miR-23b 
targets were upregulated at the protein level. In line with these findings, miR-23b was shown to 
suppress IL-17-induced NF-κB signalling and, thus, miR-23b silencing in RA was associated with 
increased inflammatory signalling (128). The authors further studied the role of miR-23b in CIA using 
miR-23b tg mice as well as adenoviral delivery of miR-23b and found that in both experimental 
settings CIA was suppressed altogether identifying miR-23b as a major inhibitor of inflammatory 
responses and potential therapeutic target in RA (128). In another paper, downregulation of miR-124a 
in RASF could be directly linked to the increased expression of MCP-1 and cyclin-dependent kinase 
(CDK) 2. Hence, miR-124a is involved in regulating the chemoattractive potential and proliferation of 
RASF (123). Finally, validating the X-linked inhibitor of apoptosis (XIAP) as a direct target of miR-
34a*, Niederer et al. connected the silencing of miR-34a* in RASF with increased XIAP levels and, 
thus, the resistance to apoptosis inherent to RASF (126). 
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Summarising the above, there is ample evidence for miRNA dysregulation in RA. Considering 
their many targets and the somehow ambiguous roles they might assume (e.g. miR-146a, miR-155) the 
question of whether individual miRNAs are suitable targets for the treatment of RA persists. Also, 
many studies have for the moment merely concentrated on measuring miRNA levels without looking 
for biological functions. Therefore, further research is indispensable to better understand the 
miRNome of RA and determine its druggability. 
 
4. Objectives 
 
EZH2 – an oncogenic histone methyltranferase in rheumatoid arthritis epigenetics 
 
RASF are key players in the pathogenesis of RA producing large amounts of matrix-degrading 
enzymes and inflammatory mediators thereby significantly contributing to chronic inflammation and 
joint destruction (19). RASF present with an activated phenotype for which the molecular basis still is 
incompletely understood. Epigenetic dysregulation offers an attractive explanation for the intrinsic 
activation of RASF (45). Whereas DNA methylation and histone acetylation have already been studied 
in the context of RA histone methylation has not been addressed yet. In an initial screen looking for 
the expression of different histone methyltransferases and demethylases EZH2 was found to be 
upregulated in RASF. With respect to the tumour-like phenotype of RASF this histone 
methyltransferase is of particular interest since it was found to be overexpressed in common solid 
tumours and therefore is considered as an oncogene participating in the epigenetic silencing of tumour 
suppressor genes (84, 85). In Chapter II of my doctoral thesis the data on the role of EZH2 in the 
activated phenotype of RASF are presented. Briefly, (i) the expression of EZH2 in RASF and (ii) the 
regulation of EZH2 by inflammatory cytokines were studied. Moreover, by experimentally 
manipulating EZH2 levels in RASF we (iii) identified an EZH2 target gene in RASF and (iv) validated 
constitutive epigenetic repression of that target gene in RASF utilising chromatin immunoprecipitation 
assays. 
 
 miR-17-92 – Oncomir-1 as a driving force of inflammation and matrix degradation 
 
The miR-17-92 cluster – also termed oncomir-1 due to the fact that it was the first miRNA 
cluster connected to the development of malignant tumours – assumes unique roles in development 
(e.g. the immune system, lung and cardiovascular system) and disease (e.g. cancer, autoimmunity) 
(141, 142). With our previous work we could show that miR-17-92, and more specifically, miR-17 and 
miR-20a, both derived from this cluster, are involved in vascular remodelling of small pulmonary 
arteries (143, 144). IL-6 could be demonstrated to upregulate the expression of miR-17-92 in 
pulmonary arterial endothelial cells and, through the action of miR-20a, to silence the bone 
Chapter I – Introduction 
 - 31 -  
morphogenic protein receptor type II, loss of which is a hallmark of the pathogenesis of pulmonary 
arterial hypertension (143, 144). We could furthermore show that miR-18a from the miR-17-92 cluster 
is part of a positive feedback loop in IL-6-induced STAT3 signalling (145). Thus, based on the known 
role of miR-17-92 in cancer, autoimmunity and our own work in pulmonary hypertension, we 
speculated whether miR-17-92 could also be involved in the pathogenesis of RA and the aggressive 
phenotype of RASF. One of the most important cytokine pathways in RA is TNFα-induced NF-κB 
signalling and, thus, in Chapter III of my doctoral thesis we show that, by forming a positive 
feedback loop,  miR-17-92 plays a similar role in TNFα-NF-κB-signalling as it does in IL-6-STAT3 
signalling. To that purpose (i) the expression of miR-17-92 in RASF in response to TNFα was 
measured and the involvement of the NF-κB pathway in miR-17-92 regulation by TNFα was 
determined. (ii) Precursor molecules of individual miRNAs from the miR-17-92 cluster were 
transfected into RASF and the expression of matrix-degrading enzymes and inflammatory mediators 
was measured to determine the contribution of those miRNAs to the inflammatory and destructive 
gene expression signature of RASF. Using computational prediction programmes and reportergene 
assays (iii) a new direct target of miR-18a was identified and (iv) its involvement in TNFα-induced 
NF-κB signalling in RASF was further validated.  
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 Expression and function of EZH2 in synovial fibroblasts: 
epigenetic regulation of the Wnt inhibitor SFRP1 in rheumatoid 
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1. Abstract 
 
Objectives: To study expression, regulation and function of the histone methyltransferase EZH2 
in synovial fibroblasts (SF) from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). 
 
Methods: SF were obtained from RA and OA patients undergoing joint surgery. Expression 
levels were assessed by quantitative real time PCR and Western blot. Kinase inhibitors and reporter 
gene assays were employed to study signalling pathways. Functional analyses included EZH2 
overexpression by plasmid transfection and gene silencing by siRNA. Chromatin immunoprecipitation 
assay was used to analyse histone methylation within distinct promoter regions. 
 
Results: By studying expression and function of EZH2 in SF we found that EZH2 is 
overexpressed in RASF and further induced by tumour necrosis factor alpha through the NF-κB and 
Jun kinase pathways. As a target gene of EZH2 we identified secreted frizzled related protein 
(SFRP)1, an inhibitor of Wnt signalling, which is associated with the activation of RASF, and show 
that SFRP1 expression correlates with the occupation of its promoter with activating and silencing 
histone marks. 
 
Conclusions: Our data strongly suggest that the chronic inflammatory environment of the RA 
joint induces EZH2 and, thus, might cause changes in the epigenetic programmes of SF. 
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2. Introduction 
 
Rheumatoid arthritis (RA) is an inflammatory disorder characterized by the progressive 
destruction of joints and bones. The pathogenesis of RA is still not completely understood so far; 
however, within the inflamed and hyperplastic synovium of RA patients, synovial fibroblasts (RASF) 
have been identified as important mediators that promote ongoing inflammation and destruction. 
These cells show an aggressive phenotype, which is characterized by the production of inflammatory 
mediators and matrix-degrading enzymes, activation of signalling pathways, and by the dysregulation 
of oncogenes and tumour suppressors (39, 146). 
Efforts to investigate the relationship of human diseases and epigenetics - defined as changes in 
gene expression that might be inherited over generations of cells but are not due to an alteration of the 
underlying nucleotide sequence - have been growing exponentially in recent years (147). Whereas 
most of these studies have been undertaken in the field of cancer research, epigenetics might also 
provide an important concept for the pathogenetic understanding of autoimmune disorders such as RA. 
In RASF, epigenetic alterations have been investigated on the level of histone acetylation (99, 106, 148) 
and DNA methylation (95). In contrast, histone methylation has not been studied yet in RASF.  
Depending on the methylated position, the methylation of histones can be associated with active 
or inactive chromatin regions. The trimethyl mark on histone 3 lysine 27 (H3K27me3) is generally 
connected with transcriptionally silenced genes. It is generated by the histone methyltransferase 
Enhancer of Zeste Homologue (EZH)2, the catalytic subunit of the polycomb repressor complex 
(PRC)2  that adds up to three methyl groups to H3K27 of genes designated for silencing (149, 150). 
Important targets of the PRCs include developmental genes, e.g. the transcription factors of the 
homeobox (HOX) gene family, or elements of signal transduction pathways such as the wingless-type 
MMTV integration site (Wnt) signalling (86, 87), which plays an important role in joint development 
and has been implicated in the pathogenesis of inflammatory arthropathies (57).  
To address the question whether RASF show epigenetic changes on the level of histone 
methylation and whether these changes might contribute to their intrinsic activation, we studied the 
role of EZH2 in RASF. 
 
3. Methods 
 
A detailed Methods section is provided in the supplementary information at the end of this chapter. 
 
Patient samples/Cell culture 
Synovial tissue samples were obtained during joint surgery from RA (n=39) and osteoarthritis (OA, 
n=22) patients.  Fibroblast cultures were maintained in Dulbecco’s modified Eagle’s medium 
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(DMEM) supplemented with 10% fetal calf serum (FCS). For stimulation experiments, cells were 
serum-starved and stimulated with 10ng/ml tumour necrosis factor alpha (TNFα; R&D Systems, 
Abingdon, UK) in presence or absence of kinase inhibitors.  
 
Quantitative real-time PCR (qPCR) 
Messenger RNA expression was quantified by TaqMan or SYBR green real-time PCR on the ABI 
Prism 7700 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland; primer 
sequences: see supplementary table S1, available online only). Data were analysed by the comparative 
Ct method with 18S rRNA employed as endogenous control.  
 
SDS-PAGE and Western blot 
For Western blot mouse-anti-EZH2 (Cell Signalling Technology), mouse anti-H3K27me3, rabbit anti-
Histone 3, rabbit anti-secreted frizzled-related protein 1 (sFRP-1) (all from Abcam), and mouse anti-α-
Tubulin (Sigma-Aldrich, Buchs, Switzerland and Abcam, Cambridge, UK) antibodies were used. 
Horseradish peroxidase-labelled species specific secondary antibodies (Jackson ImmunoResearch, 
Newmarket, Suffolk, UK) and enhanced chemiluminescence (GE Healthcare, Glattbrugg, Switzerland) 
were utilised for detection, and protein expression was quantified with Alpha Imager software. 
 
Immunohistochemistry  
To show expression of EZH2 in vivo, formalin-fixed paraffin embedded tissue sections were stained 
with mouse anti-EZH2 (BD Biosciences, Allschwil, Switzerland) and mouse anti-vimentin or mouse 
anti-CD68 (Dako, Baar, Switzerland) antibodies to demonstrate localization to fibroblasts and 
macrophages. 
 
Plasmid construction 
The coding sequence of EZH2 was cloned into the pcDNA3.1(+) vector (Invitrogen, Basel, 
Switzerland). A part of the EZH2 promoter (-1095 to +48, as described by Bracken et al. (151)) and 
the GAPDH promoter (-1087 to -24) were cloned into pGL3basic and pRL (Promega, Dübendorf, 
Switzerland).  
 
Reporter gene assay 
Using Nucleofector technology (Amaxa, Cologne, Germany) RASF were transfected with 0.5μg 
pRL_GAPDH and 2μg pGL3basic_EZH2prom (wildtype or mutated), serum-starved and stimulated 
with TNFα (10ng/ml) for 24h. Firefly luciferase activity was measured with the Dual Luciferase 
Reporter Assay System (Promega) and normalized to the activity of Renilla luciferase. 
 
Overexpression and gene silencing 
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RASF and OASF were transfected (Amaxa Nucleofection) with 1.5μg pcDNA_EZH2 or 10pmol 
siRNA (Qiagen, Hombrechtikon, Switzerland). Empty vector or AllStars Negative Control siRNA 
(Qiagen), respectively, served as controls. After 72h or 96h cells were harvested and gene 
overexpression or knockdown was analysed by qPCR and Western blot.  
 
sFRP-1 enzyme-linked immunosorbent assay (ELISA) 
To measure sFRP-1 in cell culture supernatants a sandwich ELISA was developed utilizing goat anti-
sFRP-1 (R&D Systems) as capture antibody, rabbit anti-sFRP-1 (Abcam) as detection antibody and 
horseradish peroxidase-labelled goat anti-rabbit-IgG antibody (Jackson) together with 3,3’,5,5’-
Tetramethylbenzidin for colour development.  
 
Chromatin immunoprecipation assay 
SF were fixed with 1% formaldehyde and lysed. Chromatin was sheared by sonication and pre-cleared 
with normal rabbit serum (Jackson) and Protein A beads (Upstate/Millipore, Zug, Switzerland). For 
ChIP, 1 to 2 μg of antibody (anti-Histone 3, anti-H3K4me3 (both from Abcam), anti-H3K27me3 (Cell 
Signaling Technology, Danvers, MA, USA) or normal rabbit IgG (Santa Cruz, Heidelberg, Germany)) 
was added. Chromatin was precipitated with Protein A beads, washed, eluted, reverse-crosslinked, 
digested with Proteinase K and analysed by qPCR. 
 
Statistics 
For statistical analysis GraphPad Prism 5.0 software was used. Values are presented as mean±SD. A p 
value less than 0.05 was considered significant.  
 
4. Results 
 
EZH2 is constitutively overexpressed in RASF. 
The histone methyltransferase EZH2 is associated with the epigenetic silencing of genes and has 
been found to be overexpressed in various cancers (84). Since RASF share many pathogenetic features 
with malignant cells, including alterations in the regulation of the cell cycle, adhesive properties, 
invasion to and consecutive destruction of surrounding tissues (40), we investigated the expression of 
EZH2 both in SF and in tissue sections from RA patients.  
In vitro, we found a constitutively higher expression of EZH2 mRNA in RASF as compared to 
OASF (Figure 1A). These findings were confirmed on the protein level, showing an increased 
expression of EZH2 in RASF as analysed by Western blot (Figure 1B). Furthermore, by using 
synovial tissue specimen of RA and OA patients, we found that EZH2 is expressed in vivo as well, 
both in fibroblasts (stained for the mesenchymal marker vimentin, Figure 1C) and macrophages 
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(CD68-positive cells, Figure 1D). These data indicate that EZH2 might play a role in the epigenetic 
regulation of genes in RA. 
 
 
Figure 1 EZH2 expression in RASF and synovial tissue 
A. EZH2 mRNA (relative to 18S rRNA) was increased by 1.5-fold in RASF (ΔCt: 7.61±0.63, n=15) as 
compared to OASF (ΔCt: 8.16±0.5, n=12) with higher ∆Ct values representing lower expression levels (152). B. 
EZH2 protein was increased by 1.5-fold in RASF (n=14) as compared to OASF (n=10) (ratio EZH2/α-tubulin 
RASF: 0.47±0.15, OASF: 0.32±0.1, p<0.05). C and D. In vivo, EZH2 (blue) is expressed both by fibroblasts (C, 
Vimentin+ cells, red, n=2 OA, n=2 RA) as well as by macrophages (D, CD68+ cells, red, n=2 OA, n=4 RA). As a 
smaller inset the respective IgG control is depicted in 100x magnification. 
 
Stimulation with TNFα induces EZH2. 
TNFα is a major inflammatory mediator in the pathogenesis of RA and inflammation has 
already been associated with epigenetic changes (153, 154). We thus addressed whether the addition of 
TNFα might modulate the expression levels of EZH2 in SF. As shown in Figure 2, stimulation of cells 
with TNFα increased the expression of EZH2 mRNA both in RASF and in OASF with the strongest 
effect observed after 48h (Figure 2A). Similar results were obtained by Western blot analysis for 
EZH2 protein (Figure 2B). As the catalytic subunit within the PRC2, EZH2 exerts its functional 
activity only in connection with the other PRC2 components (155). We therefore measured the 
expression of other PRC2 constituents, i.e. suppressor of zeste homologue 12 (SUZ12) and embryonic 
ectoderm development (EED) (online Supplementary Figure S1).  
 
The upregulation of EZH2 in SF does not correlate with global H3K27me3. 
Due to the primordial function of EZH2 as a distinct methyltransferase that targets lysine 27 on 
histone 3, its upregulation might lead to a concomitant increase in the methylation of its substrate. By 
addressing the global state of H3K27 trimethylation in RASF compared to OASF by Western blot, 
however, no differences in H3K27me3 could be detected between patient groups or after stimulation 
with TNFα (Figures 2C-D).  
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Figure 2 Effect of TNFα on EZH2 and H3K27me3 
A. EZH2 mRNA was significantly induced by TNFα in OASF (2.21±0.55-fold and 3.13±0.94-fold, n=6) and 
RASF (2.93±1 and 3.17±1.12-fold, n=7) after 24h and 48h, respectively. The dashed line represents the 
unstimulated control for each time point. B. EZH2 protein was induced by TNFα in OASF (2.2±0.8-fold) and 
RASF (2.1±1-fold) after 48h (p≤0.0001, n=14 and 15, respectively). C. Constitutive global H3K27me3 is not 
different in OASF and RASF (n=3 each). D. Global H3K27me3 in TNFα stimulated OASF and RASF (n=4 
each) after 48h is not changed. * p<0.05, ** p<0.005, *** p<0.001. 
 
TNFα induced upregulation of EZH2 is mediated through JNK and IKK2-dependent pathways. 
In a next step we elucidated the intracellular mechanisms involved in the TNFα induced 
upregulation of EZH2 by performing kinase inhibition experiments for the major downstream 
signalling cascades of TNFα, i.e. MAP kinases and NF-κB-pathways. The inhibition of IKK-2 
(inhibitor of nuclear factor κB kinase subunit beta) completely abrogated the induction of EZH2 
mRNA in RASF and OASF (Figure 3A), whereas the inhibition of Jun kinase (JNK) resulted in a 
partial reduction of EZH2 induction (Figure 3B). Inhibition of the p38 MAP kinase did not show any 
effects on EZH2 expression (Figure 3C).  
 
E2F acts as direct upstream transcriptional activator of EZH2. 
It has already been shown that the transcription factor E2F is a direct upstream regulator of 
EZH2 in response to serum stimulation (151). Moreover, it has been reported that its direct inhibitor 
pRb is constitutively inactivated in RASF (156). In order to investigate whether the TNFα induced 
expression of EZH2 might be due to the activation of E2F, we performed reporter gene assays with 
luciferase vectors containing the EZH2 promoter with the wildtype or a mutated binding site for E2F 
(Figure 3D). TNFα stimulation resulted in a higher activity of the EZH2 promoter as compared to 
unstimulated control. This effect was partially inhibited by mutation of the E2F binding site, indicating 
a direct interaction between E2F and the EZH2 promoter.  
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Figure 3 Regulation of TNFα induced EZH2 expression 
A. Induction of EZH2 mRNA was abrogated by pretreating SF with the NF-κB pathway inhibitor sc-514 
(IKK2i) (n=4 each). B. Induction of EZH2 mRNA was reduced by pretreating SF with the JNK inhibitor II 
(JNKi) (by 47±17% in RASF and 81±4% in OASF, n=4 each). C. Induction of EZH2 mRNA was not affected 
by pretreating SF with the p38 inhibitor SB203580 (p38i) (n=4 each). D. In reporter gene assays, the relative 
activity of the EZH2 promoter (firefly luciferase normalized to Renilla luciferase) in RASF (n=5) was increased 
after 24h TNFα stimulation by 2.1±0.6-fold. Mutation of the E2F binding site reduced the EZH2 promoter 
activation by TNFα to 1.7±0.7-fold. * p<0.05, ** p<0.005, *** p<0.001. 
 
sFRP-1 is targeted by EZH2 in SF. 
In the rheumatoid synovium the expression of agonists and antagonists of Wnt signalling was 
found to be dysregulated, among them the Wnt inhibitor sFRP-1 (157). Since elements of the Wnt 
pathway comprise known targets of EZH2 (86, 87), we investigated whether EZH2 might be involved 
in the silencing of this specific target gene in RASF. EZH2 overexpression by transfection reduced the 
levels of SFRP1 mRNA and protein in SF (Figures 4A-B). Conversely, transfection of RASF with 
siRNA targeting EZH2 resulted in a significant increase of SFRP1 mRNA at 72h (Figure 4C).  
 
 
Figure 4 Overexpression of EZH2 in RASF reduces sFRP-1 expression 
A. Overexpression of EZH2 decreased SFRP1 mRNA by 15±17% (72h) and 18±9% (96h). B. sFRP-1 protein in 
cell culture supernatants was reduced from 689±216 pg/ml to 507±56 pg/ml (minus 21.6±22.8%) after 72h and 
from 1095±101 pg/ml to 836±150 pg/ml (minus 22.9±17.7%) after 96h of EZH2 transfection, as assessed by 
ELSIA. C. Knockdown of EZH2 resulted in a significant upregulation of SFRP1 mRNA by 15±11.7% at 72h.  
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sFRP-1 is differentially expressed in RASF and OASF and is strongly repressed by TNFα. 
To test the hypothesis that SFRP1 might be epigenetically silenced in RASF, its differential 
expression between RASF and OASF was assessed. As shown in Figure 5A the expression of SFRP1 
mRNA was significantly reduced in RASF compared to OASF. Figures 5B and C emphasize that this 
was also true for the expression of sFRP-1 protein with RASF reaching only half the sFRP-1 
expression observed in OASF.  
Since EZH2 is upregulated by TNFα, and sFRP-1 appeared to be a target of EZH2-mediated 
gene silencing, we asked whether TNFα also has an impact on the expression of sFRP-1. As shown in 
Figures 5D and E stimulation of SF with TNFα strongly decreased the expression of SFRP1 mRNA 
and protein after 48h. Yet, a direct link between the TNFα induced upregulation of EZH2 and the 
downregulation of SFRP1 remains presumptive at this moment. 
 
 
Figure 5 Constitutive and TNFα regulated expression of sFRP-1 in RASF and OASF 
A. SFRP1 mRNA (relative to 18S rRNA) was reduced by 86% in RASF (∆Ct: 7.1±2, n=15) as compared to 
OASF (∆Ct: 4.5±1.7, n=12). B. Western blot analysis showed strongly reduced levels of sFRP-1 protein in 
RASF (n=10) compared to OASF (n=7) (ratio sFRP-1/α-tubulin RASF: 0.31±0.18, OASF: 0.63±0.31, p<0.05). 
C. sFRP-1 levels in supernatants of RASF (566±354 pg/ml, n=10) were reduced by 56% compared to OASF 
(1285±845 pg/ml, n=7). D. SFRP1 mRNA levels were reduced by TNFα in RASF (by 85±6%, n=6) and OASF 
(by 82±7%, n=7) with the strongest effect after 48h. The dashed line represents the respective unstimulated 
control for each time point E. sFRP-1 protein expression was decreased after 48h of TNFα stimulation in RASF 
(by 36±19%) and OASF (by 45±7%) (n=6 each, p≤0.005). * p<0.05, ** p<0.005, *** p<0.001 
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Activating and silencing chromatin marks of the SFPR1 gene promoter are different between RASF 
and OASF.  
To prove that SFRP1 is subject to EZH2 mediated silencing we performed chromatin 
immunoprecipitation (ChIP) analysis. Chromatin precipitated with antibodies against histone 3, 
H3K4me3 and H3K27me3 was analysed for enrichment in three regions of the SFRP1 promoter 
(upstream, downstream and at the transcription start site (TSS), Figure 6A). In general, the differences 
in H3K4me3 and H3K27me3 occupation of the SFRP1 promoter between RASF and OASF were 
strongest in region 3. Whereas the activating methylation of H3K4 was reduced in RASF, the 
repressive H3K27 trimethylation was increased (Figure 6B). The trends observed in promoter regions 
1 and 2 were similar but weaker than in region 3.  
 
 
Figure 6 ChIP analysis of the SFRP1 promoter in RASF and OASF 
A. Schematic representation of the SFRP1 promoter. Shaded areas represent CpG islands as calculated by 
MethPrimer (www.urogene.org/methprimer). “+1” indicates the transcription start site (TSS). Black boxes 
represent the three different amplicons for ChIP-qPCR (1: -750/-699 bp, 2: -100/-51 bp, 3: +991/+1024 bp 
relative to TSS) B. qPCR analysis of chromatin from RASF (n=10) and OASF (n=7) ChIPed with rabbit IgG, 
anti-Histone 3, anti-H3K4me3 and anti-H3K27me3. To compare different patient samples, the ratio between the 
levels of the methylation mark and total histone 3 at promoter regions was calculated. RASF showed a decreased 
trimethylation of H3K4 (ratio to H3: 0.31±0.27, OASF: 0.66±0.32) and increased H3K27me3 (ratio to H3: 
0.45±0.36, OASF: 0.22±0.08). C. ΔCt of SFRP1 mRNA in RASF (■) and OASF (▲) correlated negatively with 
the H3K4me3/H3 ratio (right) and positively with the H3K27me3/H3 ratio (left) in region 3 of the SFRP1 
promoter. 
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Since we observed a strong variability of H3K4me3 and H3K27me3 at the SFRP1 promoter 
between cells from different patients, we analysed whether this might correlate with the expression of 
SFRP1. As shown in Figure 6C, a strong positive correlation between H3K27me3 and the ΔCt value 
of SFRP1 was found (Pearson’s r=0.634). On the other hand, a high H3K4me3/H3 ratio correlated 
with a low SFRP1 ΔCt value and thus higher mRNA expression levels (r=-0.845). These data indicate 
that SFRP1 expression in RASF is reduced due to decreased H3K4me3 and increased H3K27 
methylation in its promoter. 
We also analysed other Wnt inhibitors, including Dickkopf-1 (DKK1) and SFRP2-5, but could 
only detect significant expression differences for SFRP2 (online Supplementary Figure S2). Although 
there was a general trend towards a correlation between H3K4me3 and H3K27me3 occupation of the 
promoters and Wnt inhibitor expression levels, there was not such a distinct pattern of expression 
correlating with both histone methylation marks as for SFRP1. These data suggest that the differential 
regulation by H3K4/H3K27 methylation in OASF and RASF is unique to SFRP1. 
 
5. Discussion 
 
In this study we focused on the expression and function of the histone methyltransferase EZH2 
in synovial fibroblasts of RA patients and found that a) EZH2 is overexpressed in RASF as compared 
to OASF; b) expression of EZH2 is induced by TNFα involving NF-κB and MAP-kinase pathways; 
and c) SFRP1 is a direct target gene of EZH2, whose expression pattern correlates with the occupation 
of activating and inactivating histone methylation marks in its promoter region.  
Whereas the status of histone methylation and its respective mediators has not been assessed in 
RA so far, EZH2 has been found overexpressed in different cancers and, in malignancies involving the 
prostate and breast, it has been proposed as a marker of disease progression and metastatic potential 
(158, 159). Likewise, the behaviour of cells within the rheumatoid synovium has been compared to the 
growth of an invasive tumour from which synovial fibroblasts actively invade and destroy the articular 
cartilage (1, 42, 160). Consistent with the findings from cancer tissues, we showed in the present study 
that the expression levels of EZH2 are increased in RASF and, moreover, that these levels can be 
further enhanced by TNFα stimulation. We could link this effect to the intracellular activation of NF-
κB, JNK and E2F-Rb pathways, all of which represent major signalling cascades involved in the 
activation of SF.  
Despite the induction of EZH2 expression, we could not detect changes of global H3K27me3 in 
response to TNFα. One thus could speculate that EZH2 is specifically targeted to certain chromatin 
areas so that its activity is eventually not reflected in global changes of H3K27me3. Such specific 
targeting of local chromatin areas has already been suggested by others. De Santa et al. could 
demonstrate that in macrophages the LPS-induced expression of Jmjd3, i.e. the demethylase for 
H3K27me3, did not cause alterations in global methylation of H3K27 (153). In a next step we thus 
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focused on potential target genes that might show local methylation changes in their promoters and 
identified SFRP1 as a direct target of EZH2. Decreased expression of sFRP-1 within the rheumatoid 
synovium has already been described by Imai et al.(157); here, we identified the distinct epigenetic 
mechanisms of this downregulation and unravelled the signalling pathways in RASF in vitro.   
sFRP-1 inhibits Wnt signalling by directly binding to Wnts and is thus believed to antagonize 
both the canonical and non-canonical pathways (161). Inactivation of SFRP1 by DNA methylation has 
been described among the early changes occurring in the development of colorectal cancer (162). In 
RA, canonical Wnt signalling has been shown to participate in the activation of RASF through the 
regulation of cytokines, matrix metalloproteinase (MMP)3 and production of extracellular matrix 
molecules (163, 164). Furthermore, the RA synovium has been found to contain higher levels of Wnt1, 
Wnt5A, and Wnt10B than OA or normal synovium (157, 165). It is thus highly suggestive that, by 
producing considerably less amounts of sFRP-1, the RASF is turned even more responsive to Wnt 
proteins in the synovial tissue. Inhibition of Wnt agonists or upregulation of Wnt antagonists, e.g. by 
interfering with epigenetic mechanisms, therefore appears to be favourable in the pathogenesis of RA 
regarding the attenuation of the invasive and destructive potential of RASF. On the other hand, bone 
erosions can be inhibited by blocking the Wnt inhibitor DKK1 which was found to enhance 
osteoclastogenesis and repress bone formation by osteoblasts (56, 166). The question thus arises 
whether the influence of Wnt signalling on joint destruction is cell type dependent or defined by the 
different modes of action of DKK1 and SFRPs. 
Our data indicate that the epigenetic landscape of the SFRP1 promoter in RASF is changed 
towards a transcription-inhibiting state. Overexpression of the H3K27-methyltransferase EZH2 led to 
reduced levels of SFRP1 and, conversely, silencing of EZH2 to increased SFRP1 levels. By 
comparing RASF with OASF, we could observe increased H3K27me3 with a concomitant decrease of 
H3K4me3. H3K4me3 and H3K27me3 are known to co-localise in bivalent domains which, depending 
on the type of cells, cause genes to tend towards a rather repressed or activated state (76, 77). Ke et al. 
showed that genes carrying H3K4me3 are more expressed than those carrying both H3K4me3 and 
H3K27me3, which in turn are more highly expressed than those carrying only H3K27me3 (77). 
Indeed, we have demonstrated that the SFRP1 promoter in SF contains such a bivalent domain and 
that the expression of SFRP1 correlates with both methyl marks. 
Our experiments suggest the following model of SFRP1 silencing in SF in the chronically 
inflamed RA joint. Continuous exposure to TNFα and other inflammatory mediators (see online 
Supplementary Figure S3) might lead to alterations in epigenetic programmes, e.g. through the 
induction of EZH2 expression. Trimethylation of lysine 27 of histone 3 and the loss of H3K4 
trimethylation within the promoter regions might implement the TNFα induced silencing of SFRP1 so 
that it could persist even outside the inflammatory environment. Whereas only a weak correlation 
between the EZH2 expression and SFRP1 expression was found, the levels of SFRP1 mRNA and 
methylation status of its promoter could be strongly correlated. In cell culture, RASF escape from the 
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ongoing exposure to inflammatory cytokines thus probably leading to a relative normalization of the 
EZH2 levels. This could explain the proportionally moderate increase of basal EZH2 expression in 
RASF when compared to OASF as observed in the present study. These basal expression levels of 
EZH2, however, might already be sufficient to maintain the epigenetic memory of the cells by copying 
the methyl mark on the SFRP1 gene during replication. Whether the addition of TNF antagonists in 
patients might have a similar effect and, over time, even reverse the epigenetic phenotype is 
speculative. Since our data suggest an analogous role of EZH2 in RASF and in cancer cells, it might 
be of interest for further studies to investigate EZH2 as potential marker for disease activity, in 
particular for patients with ongoing joint destruction despite treatment with TNF antagonists. 
In summary, we addressed here for the first time histone methylation in RASF and found an 
overexpression of the histone methyltransferase EZH2 thus leading to alterations in the Wnt signalling 
pathway by downregulation of the tumour suppressor gene SFRP1.  
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6. Supplementary Information 
 
Supplementary Methods 
 
Patient samples/ Cell culture 
Synovial tissue samples were obtained during joint surgery from RA and osteoarthritis (OA) patients 
after they had given written informed consent for further use of their tissue for research purposes. 
Work with patient materials was approved by the local ethics committee. For fibroblast cultures, tissue 
specimen were digested with collagenase and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). Fibroblasts from passages 4 to 9 were used. 
 
Stimulation experiments/ Inhibitor studies 
SF were starved for 16-24h in DMEM containing 0.5% FCS and stimulated with 10ng/ml TNFα 
(R&D Systems). For kinase inhibition studies, SF were pre-incubated with sc-514 (50μM, IKK-2 
inhibitor), JNK Inhibitor II (20μM), p38 inhibitor SB203580 (10μM) (all from Sigma Aldrich) or 
DMSO alone for 1h before adding TNFα. 
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SDS-PAGE and Western blot 
Whole cell lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to nitrocellulose or PVDF membranes. Membranes were blocked with 
5% milk or 2% horse serum in TBS-T and incubated with the following antibodies: mouse-anti-EZH2 
(Cell Signaling Technology), mouse-anti-H3K27me3, rabbit-anti-Histone 3, rabbit-anti-SUZ12, 
rabbit-anti-sFRP-1 (all from Abcam), sheep-anti-EED (R&D Systems), mouse-anti-α-Tubulin (Sigma-
Aldrich and Abcam). Horseradish peroxidase (HRP)-labelled species specific secondary antibodies 
(Jackson ImmunoResearch) and enhanced chemiluminescence (GE Healthcare) were utilised for 
detection, and protein expression was quantified with Alpha Imager software. 
 
Immunohistochemistry  
Formalin-fixed paraffin embedded tissue sections were deparaffinised and underwent antigen retrieval 
with 1mg/ml Trypsin for 25 min at 37°C (only for CD68 staining) and in 10mM citrate buffer (pH 6.0) 
for 30 min at 90°C. Unspecific binding was blocked by 5% goat serum in PBS (+1% BSA) before the 
sections were incubated with mouse-anti-EZH2 (BD Biosciences) or mouse IgG (Dako) (10μg/ml) 
over night at 4°C. Biotinylated secondary goat-anti-mouse antibody (Jackson ImmunoResearch), 
Vectastain ABC Kit for alkaline phosphatase and Vector Blue (Vector Laboratories) were used for 
detection. Subsequently, endogenous peroxidase was blocked with 3% H2O2 for 10 min before 
incubating with 5% goat serum in PBS (+1% BSA) for 1h. To show the expression of EZH2 in cells of 
mesenchymal origin (fibroblasts) or in macrophages, mouse-anti-vimentin or mouse-anti-CD68 
(2μg/ml, Dako) antibodies were applied over night at 4°C and detected using HRP-labelled goat-anti-
mouse antibody (for vimentin) or biotinylated goat-anti-mouse antibody and Vectastain Elite ABC Kit 
for HRP (for CD68) together with aminoethylcarbazole as chromogen. 
 
Plasmid construction 
The coding sequence of EZH2 was amplified from human cDNA and inserted into the pcDNA3.1(+) 
vector (Invitrogen) via the BamHI and XhoI restriction sites. A part of the EZH2 promoter (-1095 to 
+48, as described by Bracken et al. (151)) and the GAPDH promoter (-1087 to -24) were amplified 
from human genomic DNA and cloned into pGL3basic and pRL (Promega), respectively, via the BglII 
and HindIII sites. The E2F binding site (+33 to +40) in the EZH2 promoter was mutated by site-
directed mutagenesis in four positions. 
 
Transfection 
RASF and OASF were transfected with the Basic Nucleofector Kit for Primary Mammalian 
Fibroblasts (Amaxa) according to the manufacturer’s instructions. The medium was replaced 24h after 
transfection to remove floating cells.  
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Reporter gene assay 
RASF were transfected with 0.5μg pRL_GAPDH and 2μg pGL3basic_EZH2prom or 
pGL3basic_EZH2prom_ΔE2F. After 24h in complete medium, cells were starved for 24h (DMEM + 
0.5% FCS) and stimulated with TNFα (10ng/ml) for another 24h. Firefly luciferase activity was 
measured with the Dual Luciferase Reporter Assay System (Promega) and normalized to the activity 
of Renilla luciferase. 
 
sFRP-1 enzyme-linked immunosorbent assay (ELISA) 
To measure sFRP-1 in cell culture supernatants microwell plates were coated with goat-anti-sFRP-1 
antibody (0.5mg/ml, R&D Systems) in sodium carbonate buffer (pH 9.5) over night at 4°C (as in 
(167)). PBS with 0.05% Tween-20 was used for the washing between incubation steps. After coating, 
wells were blocked with 300μl reagent diluent (2% non-fat dry milk in PBS) for 1h at room 
temperature. Recombinant sFRP-1 (R&D Systems) was used to generate a standard curve (range: 0-
10000 pg/ml) and incubated together with the undiluted cell culture supernatants for 2h at room 
temperature. For detection, rabbit-anti-sFRP-1 antibody (1:1000, Abcam) was added for 2h. HRP-
labelled goat-anti-rabbit-IgG antibody (1:5000, Jackson) was incubated for 1h and detection was 
performed with 3,3’,5,5’-Tetramethylbenzidin. Colour development was stopped with 2N H2SO4 and 
absorbance was measured at 450 nm (with wavelength correction at 560 nm).  
 
Chromatin immunoprecipation assay 
Three million SF were fixed with formaldehyde solution for 10 min (see online Supplementary Table 
S2 for details of buffer compositions). Fixation was stopped by adding 200mM glycine. After washing 
the cells with PBS three times, lysis buffer was added. Chromatin was sheared by sonication to a size 
of 400-800 bp (Bandelin Sonopuls HD2070, 6 cycles of 10s sonication at 50% power and 1 min pause 
on ice) and 10% of the sample was removed as input control. Sonicated chromatin was diluted 1:10 
and pre-cleared for 4h by adding 10μl/ml normal rabbit serum (Jackson) and 20μl/ml Protein A beads 
(Upstate, 50% slurry in TE blocked with 1mg/ml BSA and 0.4mg/ml herring sperm DNA). Pre-
cleared chromatin was parcelled to aliquots, 1 to 2 μg of antibody (anti-Histone 3, anti-H3K4me3 
(both from Abcam), anti-H3K27me3 (Cell Signaling Technology) or normal rabbit IgG (Santa Cruz) 
was added and rotated over night at 4°C. Chromatin was precipitated with 40μl/ml Protein A beads for 
4h, washed with wash buffers I to III and finally two times TE buffer. Precipitated chromatin was 
eluted by incubating twice with elution buffer for 20 min, reverse cross-linked and digested with 
Proteinase K over night at 65°C and purified with the PCR purification kit (Qiagen). Samples were 
analysed by qPCR and normalized to the 10% input sample. Occupation of the GAPDH and MYOD 
promoters was measured as positive controls for H3K4me3 and H3K27me3, respectively. 
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Statistics 
For statistical analysis GraphPad Prism 5.0 software was used. Values are presented as mean ± 
standard deviation. Data were analysed using Student’s t-test for parametric samples and the Mann-
Whitney test or Wilcoxon signed rank test for nonparametric samples, as well as Pearson’s correlation. 
A p-value < 0.05 was considered significant. Detailed information about which statistical test was used 
for individual experiments are provided in Supplementary Table S3.  
 
 
Supplementary Figures 
 
 
Figure S1 Effect of TNFα on the PRC2 components EED and SUZ12 
A. SUZ12 and EED mRNAs were significantly induced by TNFα in OASF (n=6) and RASF (n=7) after 24h and 
48h. B. EED (n=5 OASF, n=8 RASF) and SUZ12 protein expression after 48h TNFα stimulation.  SUZ12 
protein was induced in OASF (2.6±2.2-fold, p=0.001, n=11) and RASF (1.8±0.8-fold, p=0.0002, n=14). 
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Figure S2 mRNA expression of different Wnt inhibitors and occupation of their promoters with 
H3K27me3 and H3K4me3 
A. Similar to SFRP1, the expression of SFRP2 was significantly reduced in RASF. Also, SFRP4, which showed 
the highest expression of all Wnt inhibitors measured (ΔCt RASF: 2.43±1.54, OASF: 1.67±1.3), was reduced in 
RASF; the reduction observed, however, did not reach statistical significance. In contrast, DKK1 showed a trend 
towards higher expression in RASF. SFRP3 was only weakly expressed and levels of SFRP5 mRNA could not 
be detected (n.d.). B. The occupation of the SFRP2 promoter with H3K27me3 was comparable to that of SFRP1. 
The promoters of DKK1 and SFRP4 showed low levels of H3K27me3. The H3K27me3 occupation of the 
promoters for SFRP2, SFRP3 and SFRP5 tended to be higher in RASF than in OASF; these differences were not 
statistically significant. Interestingly, the activating H3K4me3 mark was absent at the SFRP3 and SFRP5 
promoters in both OASF and RASF, which may – at least in part – explain the low (SFRP3) or missing (SFRP5) 
mRNA expression of these Wnt inhibitors. In contrast, the DKK1 and SFRP4 gene promoters contained high 
levels of H3K4me3, most likely accounting for their high mRNA expression levels. However, different to 
SFRP1, we could not correlate H3K4me3/H3 and H3K27me3/H3 ratios of DKK1 and SFRP2-5 to their 
respective mRNA expression levels. H3K4me3 and H3K27me3 levels at the promoters of GAPDH and MYOD 
are shown as positive (GAPDH for H3K4me3, MYOD for H3K27me3) and negative controls (GAPDH for 
H3K27me3, MYOD for H3K4me3), respectively. (RASF: n=4-15, OASF: n= 4-12) 
 
 
Figure S3 Effect of interleukin-1β (IL-1β) and toll-like receptor (TLR) ligands on the expression 
of EZH2 and SFRP1 
Similar to stimulation with TNFα,  treatment of RASF (n=5) with the TLR3 ligand poly(I:C) led to upregulation 
of EZH2 (A) and downregulation of SFRP1 (B) after 48h. Additionally, SFRP1 mRNA expression was reduced 
by stimulation with the TLR2 ligand Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-OH (Pam3). IL-1β and 
the TLR4 ligand lipopolysaccharide (LPS) did not have an effect on the mRNA levels of EZH2 or SFRP1. The 
dashed line represents the unstimulated control. * p<0.05, ** p<0.005. 
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Supplementary Tables 
 
Table S1 Primers for qPCR  
gene expression analysis   
18S rRNA assay from Applied Biosystems (Cat. No. 4310893E) 
DKK1 for 5’ - CCA GAC CAT TGA CAA CTA CCA G – 3’ 
DKK1 rev 5’ - TGC CGC ACT CCT CGT CCT C – 3’ 
EZH2 for 5’ – AGT GTT ACC AGC ATT TGG AGG G – 3’ 
EZH2 rev 5’ – CGG TGA GAG CAG CAG CAA AC – 3’ 
EED for 5’ - GCA ATC CAG ACC TCT CTG GAG - 3’ 
EED rev 5’ - CCA CTT TCT ATA CTG ACA GCG TC - 3’ 
SFRP1 for 5' - TGA GGC CAT CAT TGA ACA TC - 3' 
SFRP1 rev 5' - TCA TCC TCA GTG CAA ACT CG - 3' 
SFRP2 for 5’ - AGC GAC CAC CTC CTG CCA G – 3’ 
SFRP2 rev 5’ - CAG GCT TCA CAT ACC TTT GGA G – 3’ 
SFRP3 for 5’ - CTA GTA ACG GAA ACT GTA GAG GG – 3’ 
SFRP3 rev 5’ - CTT ACA TTT ACA GCG TTC ACT GC – 3’ 
SFRP4 for 5' - GCC TTT CCT GTA CCA TCA TGT C - 3' 
SFRP4 rev 5' - CCG GAG GAT GTT AAG TGG ATA G - 3' 
SFRP5 for 5’ - TGC TCC AGT GAC TTT GTG GTC – 3’ 
SFRP5 rev 5’ - CCC ATT CTC TAT CTT GAT CTC C – 3’ 
SUZ12 for 5’ - GGG AGA CTA TTC TTG ATG GGA AG - 3’ 
SUZ12 rev 5’ - GAG AAA ATG TTT CGA ATG GAG GC - 3’ 
    
ChIP analysis   
DKK1 TSS for 5’ - GTA TAA AGG CAG CCG CGG TG – 3’ 
DKK1 TSS rev 5’ - TCC CAG AGT CCT GAC TGC AG – 3’ 
GAPDH for 5’ - TCG ACA GTC AGC CGC ATC TTC – 3’ 
GAPDH rev 5’ - CTA GCC TCC CGG GTT TCT CT – 3’ 
MYOD for 5’ - CCG CCT GAG CAA AGT AAA TGA G – 3’ 
MYOD rev 5’ - TGG GCA ACC GCT GGT TTG GAT – 3’ 
SFRP1 up for (region 1) 5’ - CTT CCT GAA CCC CTG TTA GTT G – 3’ 
SFRP1 up rev (region 1) 5’ - TCT AGC TGC GGT GCA GAC AG  – 3’ 
SFRP1 TSS for (region 2) 5’ - TGA CGG ACG TGG TAA CGA GTG – 3’ 
SFRP1 TSS rev (region 2) 5’ - AGC CAA TCA GCT CCC GGC G – 3’ 
SFRP1 down for (region 3) 5’ - CGT GAT TCC TAA GCG CGT CTG – 3’ 
SFRP1 down rev (region 3) 5’ - GAG GGG CGC TGA GCG ATA C – 3’ 
SFRP2 TSS for 5’ - CCG GTG TCC CGC TTC TCC – 3’ 
SFRP2 TSS rev 5’ - TCT TCG CTG GGT GCG ACT C – 3’ 
SFRP3 TSS for 5’ - TTG GGA AAG AGC AGC CTG GG – 3’ 
SFRP3 TSS rev 5’ - CTT TAC CGA GCT CCA GCC AC – 3’ 
SFRP4 TSS for 5’ - AGC TGC CAA GGG AGC GTT C – 3’ 
SFRP4 TSS rev 5’ - CCA TTG CGG GAC CCT ATT TAT C – 3’ 
SFRP5 TSS for 5’ - GAG GAA AAT GCC CAG GGA GG – 3’ 
SFRP5 TSS rev 5’ - CCT CGC CCA GCG TTT CTC C – 3’ 
 
Chapter II – Expression and function of EZH2 in synovial fibroblasts: epigenetic regulation of the Wnt inhibitor 
SFRP1 in rheumatoid arthritis 
 - 50 -  
Table S2 Buffers for ChIP 
Formaldehyde Solution Lysis buffer * Dilution Buffer* Wash Buffer 1* 
        
1% formaldehyde 50mM Tris/HCl pH 8.0 20mM Tris/HCl pH 8.0 20 mM Tris-HCl pH 8.0 
4.5mM HEPES pH 8.0  1% SDS 150mM NaCl 150 mM NaCl 
9mM NaCl 5mM EDTA 2mM EDTA 2 mM EDTA  
0.09mM EDTA   1% Triton X-100 1% Triton X-100 
0.045mM EGTA    0.1% SDS 
in PBS      
        
Wash Buffer 2* Wash Buffer 3* Elution Buffer  
       
20 mM Tris-HCl pH 8.0 10 mM Tris-HCl pH 8.0 0.1M NaHCO3  
500 mM NaCl 0.25 M LiCl 1% SDS  
2 mM EDTA 1 mM EDTA    
1% Triton X-100 1% deoxycholate    
0.1% SDS 1% NP-40    
       
       
*supplemented with 1x Protease Inhibitor Cocktail (Roche)  
 
Table S3 Statistical tests 
 
 test used student's t-test 
Mann-Whitney 
test 
Wilcoxon signed 
rank test 
Pearson's 
correlation 
Figure           
1 A        
  B        
2 A        
  B (OASF)   (RASF)   
3 A        
  B        
  C        
  D        
4 A        
  B        
  C        
5 A        
  B        
  C        
  D        
  E        
6 B        
  C        
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1. Abstract 
 
Objective: To elucidate whether the microRNA (miRNA) cluster miR-17-92 contributes to the 
activated phenotype of rheumatoid arthritis synovial fibroblasts (RASF).  
 
Methods: RASF were stimulated with tumor necrosis factor alpha (TNFα) and expression and 
regulation of the miR-17-92 cluster were studied using quantitative real-time PCR (qPCR) and 
promoter activity assays. RASF were transfected with single precursor molecules of miRNAs from 
miR-17-92 and the expression of matrix-degrading enzymes and cytokines was measured by qPCR 
and enzyme-linked immunosorbent assay. Potential miRNA targets were identified by computational 
prediction and validated using reporter gene assays and Western blot. The activity of NF-κB signaling 
was determined by reporter gene assay. 
 
Results: We found that TNFα induces the expression of miR-17-92 in RASF in a nuclear factor 
kappa B (NF-κB)-dependent manner. Transfection of RASF with precursor molecules of single 
members of miR-17-92 revealed significantly increased expression levels of matrix-degrading 
enzymes, proinflammatory cytokines and chemokines in pre-miR-18a-transfected RASF. Using 
reporter gene assays we identified the NF-κB pathway inhibitor TNFα-induced protein 3 (TNFAIP3) 
as a new target of miR-18a. In consequence, pre-miR-18a-transfected RASF showed stronger 
activation of NF-κB signaling, both constitutively and in response to TNFα-stimulation. 
 
Conclusion: Our data suggest that the miR-17-92-derived miR-18a contributes to cartilage 
destruction and chronic inflammation in the joint through a positive feedback loop in NF-κB signaling 
with concomitant upregulation of matrix-degrading enzymes and inflammatory mediators in RASF. 
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2. Introduction 
 
The microRNA-17-92 (miR-17-92) cluster has been associated with the maturation of the 
immune system and the development of hematopoietic tumors and other malignancies (142, 168, 169). 
The polycistronic primary transcript C13orf25 encodes six distinct members of the cluster: miR-17, -
18a, -19a, -19b, -20a and -92a (168, 170). Amplification of miR-17-92 has been observed in malignant 
diseases leading to growth and survival advantages due to the silencing of tumor suppressor genes 
such as the cyclin-dependent kinase inhibitor 1A (p21), phosphatase and tensin homolog (PTEN) or 
Bcl-2 interacting protein Bim by individual miR-17-92 members (168, 169, 171-173). miR-17-92 
knockout mice, on the other hand, displayed skeletal defects during embryogenesis (174) and died 
directly after birth due to severe developmental defects of the lung and the heart (175), whereas a 
moderate overexpression of miR-17-92 in the lymphoid lineage led to lymphoproliferative disease and 
autoimmunity in mice (171). Interestingly, the expression of miR-17-92 is triggered by inflammatory 
cytokines such as interleukin (IL)-6 (143, 145). 
Rheumatoid arthritis (RA) is a chronic inflammatory disease ultimately leading to the 
destruction of joints and bones. The etiology of RA is unknown so far; it is clear, however, that the 
disease is driven by infiltrating immune cells as well as resident cells of the joint, and the mutual 
interaction between these cells (1). In this regard, RA synovial fibroblasts (SF) have been identified as 
pathogenetic key players. Within the inflamed synovium, RASF are stimulated by cytokines and other 
molecules to activate major signaling pathways, which leads to overproduction and secretion of 
inflammatory mediators and matrix-degrading enzymes. Immune cells are attracted to the synovium 
and activated by RASF-secreted cytokines and, in turn, stimulate RASF resulting in a self-sustaining 
cycle of chronic joint inflammation (19). Due to the disturbed expression pattern of various proto-
oncogenes and tumor suppressors the aggressive phenotype of the RASF has been compared with the 
behavior of a locally invading tumor (42), and, as such, these cells promote adhesion to and 
destruction of articular cartilage (1, 39). Similar to the pathogenesis of malignant tumors, an aberrant 
expression of several microRNAs (miRNAs) has recently been associated with the pathogenesis of RA 
(176).  
miRNAs are characterized by their ability to target different mRNAs simultaneously, which 
might influence several signaling pathways at once. miRNAs are considered to act by fine-tuning gene 
expression; the effects of a single miRNA on a specific target thus might be rather weak, however, by 
repressing many targets at the same time a significant alteration of gene expression can occur (113, 
177).  
We have previously shown that IL-6 induces miR-17-92 both in pulmonary arterial endothelial 
cells and in human hepatocytes, in the latter ones enhancing the acute-phase response (143, 145). Thus, 
to further elucidate the role of miR-17-92 in inflammatory processes we studied here expression and 
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function of miR-17-92, in particular of miR-18a, in RASF in relationship with tumor necrosis factor 
alpha (TNFα), one of the major pro-inflammatory cytokines in the pathogenesis of RA (48, 54). 
 
3. Materials and Methods 
 
Patient samples/ Cell culture 
Synovial fibroblast cultures were established by collagenolytic digestion of synovial tissue specimens 
obtained during joint surgery from RA patients fulfilling the 1987 American College of Rheumatology 
criteria for RA (16) (kindly provided by Dr. C. Kolling of the Schulthess Clinic, Zurich, Switzerland). 
Fibroblast cultures were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% fetal calf serum (FCS) or in Roswell Park Memorial Institute 1640 (RPMI) medium (only 
for leukocyte transwell migration assay). For stimulation experiments, cells were serum-starved (0.5% 
FCS) and stimulated with 10ng/ml TNFα (R&D Systems). To inhibit NF-κB signaling, RASF were 
treated with 50 µM sc-514 (Merck-Millipore) (or DMSO as control) for 1h before TNFα was added. 
 
Quantitative real-time PCR 
mRNA and miRNA expression were quantified by SYBR Green real-time polymerase chain reaction 
(PCR) on the ABI Prism 7900 HT Sequence Detection System. Primer sequences were: 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for 5’-GGGAAGCTTGTCATCAATGGA-3’, 
GAPDH rev 5’-TCTCGCTCCTGGAAGATGGT-3’, C13orf25 for 5’-
TTGCTAAGTGGAAGCCAGAAG-3’, C13orf25 rev 5’-CATCCACGTGGCAAAACAT-3’ (as 
described by O’Donnell et al. (178)), matrix metalloproteinase (MMP) 1 for 5’-
GCTAACAAATACTGGAGGTATGATG-3’, MMP1 rev 5’-
ATTTTGGGATAACCTGGATCCATAG-3’, IL6 for 5'-CCCTGAGAAAGGAGACATGTAAC-3’, 
IL6 rev 5’-CCTCTTTGCTGCTTTCACACATG-3’, IL8 for 5’-TTGGCAGCCTTCCTGATTTC-3’, 
IL8 rev 5’-TGGCAAAACTGCACCTTCAC-3’, monocyte chemoattractant protein (MCP) 1 for 5’-
CTCGCTCAGCCAGATGCAATC-3’, MCP1 rev 5’-AAGTTATAACAGCAGGTGACTGG-3’, 
RANTES for 5’-CCAACCCAGCAGTCGTCTTTG-3’, RANTES rev 5’-
TGGCACACACTTGGCGGTTC-3’. miRNAs were quantified by stem-loop reverse transcription 
(RT)-PCR according to Chen et al. (179) using the following primers: miR-18a RT 5’-
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTATCT-3’, miR-18a for 
5’-GGCGGTAAGGTGCATCTAGT-3’, miR-19 RT 5’-
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCAGTT-3’, miR-19a for 
5’-CGGCGGTGTGCAAATCTATGC-3’, miR-92a RT 5’-
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACAGGC-3’, miR-92a for 
5’-CGGCGGTATTGCACTTGTCCC-3’, universal miR rev 5’-GTGCAGGGTCCGAGGT-3’, miR-
20a RT 5’-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTACCTG-3’, 
miR-20a for 5’-CCTTAAAGTGCTTATAGTGCAG-3’, miR-20a rev 5’-
Chapter III – The TNFα-induced miR-18a activates rheumatoid arthritis synovial fibroblasts through a feedback 
loop in NF-κB signalling 
 - 55 -  
TGCAGGGTCCGAGGTAT-3’. Data were analyzed by the comparative Ct method with GAPDH 
mRNA employed as endogenous control. 
 
Plasmid construction 
A part of the C13orf25 promoter (-1341 to +11, as described in (180)) was cloned into pGL3basic and 
the GAPDH promoter (-1087 to -24) was cloned into pRL (Promega). The 3’ untranslated regions 
(3’UTRs) of dual-specific phosphatase 16 (DUSP16; 1-936 bp), protein tyrosine phosphatase type IV, 
member 3 (PTP4A3; 1-476bp) and TNF alpha-induced protein 3 (TNFAIP3; 1-1996bp) were cloned 
into pmirGLO (Promega). Site-directed mutagenesis PCR was used to mutate the NF-κB binding site 
(-959 to -950) in the C13orf25 promoter construct and the miR-18a seed matches in the 3’UTR 
constructs (DUSP16: 392-398bp; PTP4A3: 405-412bp; TNFAIP3: 671-677bp). 
 
Transfection of small RNAs 
RASF were transfected with 25nM precursor-miRNAs (pre-miR) or 100nM anti-miR-18a (both from 
Ambion) using Lipofectamin 2000 (Invitrogen). After 6h or 24h, the transfection mixture was replaced 
by fresh medium. Small interfering RNAs (siRNAs, 100nM; Qiagen) were transfected using the 
Primary Mammalian Fibroblast Nucleofection Kit (AMAXA/Lonza). Pre-miR Negative Control #1, 
anti-miR Negative Control #1 and AllStars Negative Control siRNA, respectively, served as 
transfection controls. 24h or 48h after transfection, cells were serum-starved for another 24h and 
stimulated with TNFα as indicated.   
 
Reporter gene assay 
Using nucleofector technology (AMAXA/Lonza), RASF were transfected with 1.2μg pRL_GAPDH 
and 1.8μg pGL3basic_C13orf25prom (wildtype or mutated), after 24h serum-starved for another 24h, 
and stimulated with TNFα (10ng/ml) for 8h. To measure NF-κB activity, RASF were transfected with 
1.2μg pRL_GAPDH and 1.8μg pGL4.32 (five NF-κB response elements in row; Promega) by 
AMAXA Nucleofection. After 24h, RASF were transfected with pre-miR negative control #1 or pre-
miR-18a using Lipofectamin 2000 as described above. 48h later, cells were serum-starved for 24h and 
stimulated with TNFα (10ng/ml) for 5h.  
Using Lipofectamin 2000, Hek293 cells were transfected with 180ng pRL_GAPDH and 360ng 
pGL3basic_C13orf25prom (wildtype or mutated) and stimulated with TNFα (10ng/ml) for 4h and 8h. 
For the validation of miR-18a targets, Hek293 cells were transfected with 230ng pmirGLO_DUSP16, 
pmirGLO_TNFAIP3 or pmirGLO_PTP4A3 (wt or mutated miR-18a seed match) together with 25nM 
pre-miR negative control #1 or pre-miR-18a and harvested after 24h.  
Firefly luciferase activity was measured with the Dual Luciferase Reporter Assay System (Promega) 
and normalized to the activity of Renilla luciferase. An arbitrary cut-off of 1000 relative luciferase 
units was used for data analysis. 
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MMP-1, IL-6, IL-8, MCP-1 and RANTES ELISA 
To measure MMP-1, IL-6, IL-8, MCP-1 and RANTES in cell culture supernatants commercially 
available ELISA development kits were used (MMP-1 and RANTES: R&D Systems; IL-6, IL-8 and 
MCP-1: BD Biosciences).  
 
Isolation of peripheral blood leukocytes 
Fresh blood from healthy donors was diluted with 1 volume isotonic NaCl solution and treated with 8 
volumes hypotonic erythrocyte lysis buffer (155mM NH4Cl, 10mM NaHCO3, 0.1mM EDTA, pH7.4) 
for 5 min on ice. After centrifugation, lysis was repeated with 4 volumes and then 1.5 volumes 
erythrocyte lysis buffer in isotonic NaCl. Cells were washed twice with ice-cold phosphate buffered 
saline (PBS), counted and resuspended in RPMI medium at a concentration of 107 cells/ml. 
 
Leukocyte transwell migration assay 
In 100µl volume, 1x106 leukocytes per insert were seeded to a 96-well transwell plate (5µm 
polycarbonate membrane, Corning Costar). Medium (RPMI supplemented with 0.5% FCS) or 
conditioned medium (CM, 150µl per well) from pre-miR-18a or control transfected RASF was added 
to the feeder tray beneath the transwell. Leukocytes were allowed to migrate for 6h. To facilitate 
detachment of adhered cells, 50µl ice-cold 20mM EDTA/0.5% FCS in PBS was added to the lower 
wells and plates were incubated on ice for 15min. Migrated cells were counted with a CASY Cell 
Counter (Schärfe Systems). Leukocytes from two different healthy donors were used for analysis of 
each CM preparation and vice versa. All conditions were measured in duplicates.  
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot 
For Western blot, rabbit-anti-TNFAIP3 (Abcam), mouse-anti-PTP4A3 (R&D Systems), and mouse-
anti-α-tubulin (Sigma-Aldrich and Abcam) antibodies were used. Bands were detected utilizing 
horseradish peroxidase-labeled species specific secondary antibodies (Jackson ImmunoResearch) and 
enhanced chemiluminescence (GE Healthcare). Protein expression was quantified by spot 
densitometry with Alpha Imager software (Alpha Innotech) or Bio-1D software (Vilber Lourmat). 
 
Statistics 
For statistical analysis, GraphPad Prism 5.0 software was used. Data were tested for Gaussian 
distribution using the Shapiro-Wilk normality test and were analyzed by parametric (two-tailed paired 
t-test) or non-parametric (Wilcoxon matched-pairs signed rank test) statistical tests as appropriate. 
Values are presented as mean±standard deviation (SD). A p-value < 0.05 was considered significant. 
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4. Results 
 
TNFα induces the expression of C13orf25 and mature miRNAs from the miR-17-92 cluster in RASF 
TNFα is one of the major cytokines in the pathogenesis of RA (48, 54). Therefore we 
investigated whether TNFα could influence the expression of miR-17-92 in RASF. Figure 1A 
demonstrates that the primary transcript of miR-17-92, C13orf25, was induced by TNFα in a time-
dependent manner. Accordingly, mature miRNAs derived from miR-17-92 – i.e. miR-18a, -19a, -20a 
and 92a – were upregulated at 8h and 16h of TNFα stimulation (Figure 1B).  
 
 
 
The TNFα-induced C13orf25 expression depends on a NF-κB binding site in its promoter 
TNFα is an important inducer of NF-κB and Jun kinase (JNK) signaling. To study whether 
C13orf25 induction by TNFα depends on these pathways, we treated RASF with sc-514, a chemical 
inhibitor of the Inhibitor of IκB kinase β which is upstream of NF-κB nuclear translocation. sc-514 
partly inhibited TNFα-induced C13orf25 expression (Figure 1C). Figure 1D shows the expression of 
TNFAIP3, an established NF-κB target gene and negative regulator of NF-κB signaling in RASF (67, 
181), which was used as positive control for effective inhibition of NF-κB signaling by sc-514. In 
Figure 1 TNFα induces the expression of the 
miR-17-92 cluster via an NF-κB binding site 
in the C13orf25 promoter. 
A. RASF (n=4-16) were stimulated with TNFα 
for the indicated time points. The C13orf25 
primary transcript was significantly induced at 
8h, 16h and 24h of stimulation. B. TNFα 
stimulation for 8h and 16h increased the levels 
of mature miRNAs - miR-18a, -19a, -20a and -
92a – from miR-17-92 in RASF (n=15-16). C 
and D. RASF (n=5) were treated with sc-514 
and stimulated with TNFα. sc-514 reduced the 
TNFα-induced induction of C13orf25 (at 16h; 
C) and TNFAIP3 (D). E and F. RASF (n=6; E) 
and Hek293 cells (n=5; F) were transfected with 
reportergene constructs encompassing the 
C13orf25 promoter with wildtype (wt) or 
mutated (∆NF-κB) NF-κB binding site and 
stimulated with TNFα for 4h and/or 8h. 
C13orf25 promoter activity was induced in the 
wt construct whereas mutation of the NF-κB 
binding site inhibited the TNFα-mediated 
increase in C13orf25 promoter activity. Data are 
presented as mean±SD. ns=not significant, * 
p<0.05, ** p<0.01, ***p<0.001 by paired t-test 
or Wilcoxon matched-pairs signed rank test. 
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contrast, treating RASF with the JNK inhibitor SP600125 did not affect TNFα-induced C13orf25 
expression (data not shown). 
Zhou et al. previously demonstrated that the C13orf25 promoter contains three NF-κB binding 
sites of which the most proximal to the transcription start site (at -827bp) is responsible for LPS-
induced C13orf25 transactivation in human biliary epithelial cells (182). We therefore addressed 
whether the TNFα−induced transcription of C13orf25 in RASF depends on this NF-κB binding site by 
utilizing a reportergene construct encompassing the C13orf25 promoter with wildtype or mutated NF-
κB binding site controlling the firefly luciferase gene. The C13orf25 promoter activity was enhanced 
in RASF stimulated with TNFα for 8h and this induction was diminished when using the C13orf25 
promoter construct in which the NF-κB binding site had been mutated (Figure 1E). Similar results 
were obtained when Hek293 cells were used for the reportergene assay (Figure 1F) suggesting that 
NF-κB-dependent induction of C13orf25 by TNFα is a general mechanism which might be applicable 
to other cell types than RASF. Since NF-κB blockade and NF-κB binding site mutation, however, did 
not completely abolish TNFα-dependent C13orf25 induction other pathways might be involved in this 
process as well. 
 
Enforced expression of miR-18a upregulates MMP-1, IL-6, IL-8, MCP-1 and RANTES and increases 
the chemoattractive potential of RASF 
A major hallmark of RASF is the production of matrix-degrading enzymes and inflammatory 
mediators, i.e. cytokines and chemokines, contributing to cartilage degradation and infiltration of the 
joint by immune cells (19). To elucidate which role miRNAs from the miR-17-92 cluster might play in 
the activation of RASF we chose the expression of MMP1 as a functional read-out for the effect of 
miR-17-92 transfection on RASF. We transfected RASF with precursor molecules of miR-18a, -19a, -
20a and -92a (pre-miRs) (representing the four different miRNA families of the cluster) and 
subsequently stimulated with TNFα for 6h. Only pre-miR-18a transfection led to a significant increase 
in both the constitutive and the TNFα-induced expression of MMP1 mRNA (Figure 2A). Our further 
experiments thus were focused on this miRNA. To get a deeper insight into the role of miR-18a in the 
activation of RASF we measured MMP-1, IL-6, IL-8, MCP-1 and RANTES in pre-miR-18a- and anti-
miR-18a-transfected RASF at the mRNA level (Figures 2B and 2C). The constitutive expression of 
MMP-1, IL-6, MCP-1 and RANTES was increased by pre-miR-18a transfection, and the TNFα-
induced upregulation (at 24h stimulation) of MMP-1, IL-6, IL-8, MCP-1 and RANTES was further 
enhanced by pre-miR-18a transfection. Conversely, inhibition of miR-18a using anti-miR-18a 
significantly reduced the expression of IL8 and MCP1 under unstimulated conditions. In TNFα-
treated cells, antagonizing miR-18a showed a trend towards reduced cytokine expression. These 
results, however, did not reach statistical significance. One can speculate that in TNFα-stimulated 
cells anti-miR-18a blocks miR-18a only in an inefficient manner (Figure 2D). In this regard, TNFα  
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Figure 2 The miR-17-92-derived miR-18a promotes the expression of matrix-degrading enzymes 
and inflammatory mediators in RASF. 
A. RASF (n=5) were transfected with precursor molecules of single miRs and stimulated with TNFα for 6h. B. 
RASF (n=8) were transfected with pre-miRs and after 48h stimulated with TNFα for 24h. mRNA levels of all 
studied genes were increased in pre-miR-18a-transfected RASF in unstimulated conditions (with the exception 
of IL8) and following TNFα stimulation. C. RASF (n=8) were transfected with anti-miR-18a and after 24h 
stimulated with TNFα for 24h. IL8 and MCP1 mRNA levels were reduced in unstimulated anti-miR-18a-
transfected RASF. D. miR-18a was overexpressed (left) and silenced (right) in RASF studied in B and C. Data 
are presented as mean±SD. ns=not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by paired t-test 
or Wilcoxon matched-pairs signed rank test. 
 
seems to counteract the anti-miR-18-mediated inhibition of miR-18a by inducing the expression of 
miR-18a in RASF. Our data indicate that miR-18a contributes to the activation of RASF by 
upregulating the expression of important mediators of matrix infiltration and degradation.  
To further corroborate our findings we measured secreted protein levels of MMP-1, IL-6, IL-8, 
MCP-1 and RANTES in the supernatants of RASF transfected with pre-miR-18a. Analogous to the 
mRNA data (Figure 2B), miR-18a-overexpressing RASF secreted higher levels of MMP-1 and the 
cytokines investigated than control cells (Figure 3A).To determine whether the effects of miR-18a on 
RASF gene expression, in particular the increased secretion of the chemokines IL-8, MCP-1 and 
RANTES, might indeed play a functional role in the pathogenesis of RA we performed a transwell 
migration assay using peripheral blood leukocytes from healthy donors and conditioned medium (CM) 
from RASF transfected with pre-miR-18a and stimulated with TNFα placed in the lower compartment 
as a chemoattractant. Figure 3B demonstrates that CM from pre-miR-18a-transfected and TNFα- 
stimulated RASF attracted more leukocytes towards the lower chamber than from scrambled control 
RASF. These experiments show that miR-18a upregulation in RASF increases the chemoattractive 
potential of these cells and, thus, might contribute to the infiltration of the inflamed joint with immune 
cells. 
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Figure 3 miR-18a confers increased chemoattractive potential to RASF. 
A. Levels of MMP-1, IL-6 and of the chemokines IL-8, MCP-1 and RANTES were increased in the supernatants 
of pre-miR-18a-transfected RASF (n=8, same as in Figure 2B). # MMP-1 levels from unstimulated scr RASF 
were detected below the lowest standard value (156 pg/ml). B. In a transmigration assay, conditioned medium 
(CM) from pre-miR-18a-transfected and TNFα-stimulated RASF (n=8) attracted increased numbers of 
leukocytes towards the lower chamber. Leukocyte migration towards CM from unstimulated RASF was similar 
to background migration (i.e. medium only instead of CM). Data are presented as mean±SD. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 by paired t-test or Wilcoxon matched-pairs signed rank test. 
 
miR-18a directly targets the NF-κB signaling inhibitor TNFAIP3 in RASF 
In RASF, the expression of MMPs, cytokines and chemokines depends on the activation of 
important signaling pathways such as NF-κB, p38 and JNK signaling (183, 184). Based on the fact 
that miRNAs are negative regulators of gene expression while, on the other hand, we found miR-18a 
to upregulate downstream targets of TNFα signaling in RASF, we hypothesized that miR-18a might 
repress inhibitors of signal transduction pathways. Using the TargetScan database 
(www.targetscan.org) for computational prediction of miRNA targets we selected the NF-κB pathway 
inhibitor TNFAIP3 (181), the p38 phosphatase PTP4A3 (185) and the JNK phosphatase DUSP16  
(186) as potential candidates for target validation. Since miRNAs repress gene expression by binding 
to the 3’UTRs of mRNAs leading to mRNA degradation and/or inhibition of translation (113, 177), 
we cloned the 3’UTRs of the three potential miR-18a targets into a reporter vector downstream of the 
luciferase gene. Co-transfection of these reporter vectors with pre-miR-18a into Hek293 cells reduced 
the luciferase activity when it was under control of the TNFAIP3 and PTP4A3 3’UTRs. Pre-miR-18a 
also reduced the DUSP16 3’UTR-controlled luciferase activity, however, without reaching statistical 
significance. Mutation of the respective miR-18 seed matches in those 3’UTRs rescued luciferase 
activity in miR-18a transfected cells (Figure 4A). These data indicate that miR-18a directly represses 
TNFAIP3 and PTP4A3 via the miR-18 seed matches in their 3’UTRs.  
Subsequently, we analyzed the expression of TNFAIP3 and PTP4A3 in RASF transfected with 
pre-miR-18a. Whereas PTP4A3 mRNA levels were not affected TNFAIP3 mRNA expression was in-  
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Figure 4 The NF-κB signaling pathway inhibitor TNFAIP3 is a direct target of miR-18a in RASF. 
A. Utilizing reporter vectors encompassing the 3’ untranslated regions (UTRs) of TNFAIP3, PTP4A3 and 
DUSP16, pre-miR-18a transfection significantly reduced the luciferase activity of the wildtype (wt) TNFAIP3 
and PTP4A3 reporter constructs; mutated miR-18a seed matches (∆miR-18) rescued the luciferase activity back 
to levels of scr transfected cells (n=4 each). B. pre-miR-18a transfection increased TNFAIP3 mRNA levels 
whereas PTP4A3 mRNA levels were not influenced in RASF (n=8, same as in Figure 2B). C. Protein expression 
of TNFAIP3 was reduced in RASF (n=7) transfected with pre-miR-18a for 48h whereas PTP4A3 levels were not 
affected (quantification in D). Data are presented as mean±SD. ns=not significant, *p<0.05, **p<0.01, 
***p<0.001 by paired t-test or Wilcoxon matched-pairs signed rank test. 
 
creased in RASF overexpressing miR-18a (Figure 4B). Since miRNAs often only inhibit translation 
and do not mediate degradation of the target mRNA, we also measured protein levels of TNFAIP3 and 
PTP4A3 in miR-18a transfected RASF (Figures 4C and D). Despite directly targeting the PTP4A3 
3’UTR in the reporter gene assay miR-18a transfection failed to reduce PTP4A3 levels in RASF. In 
contrast, TNFAIP3 protein levels were reduced at 48h after transfection. This discrepancy with the 
increased mRNA levels of TNFAIP3 might be explained by the fact that TNFAIP3 itself is a negative 
feedback regulator of NF-κB and, thus, translational repression of TNFAIP3 by miR-18a in RASF 
may induce the transcriptional activation of TNFAIP3 via enhancing NF-κB signaling. 
 
Concomitant upregulation of C13orf25 and TNFAIP3 in TNFα-stimulated RASF 
We next examined the expression of TNFAIP3 and C13orf25 in matched TNFα-stimulated 
RASF samples. Transcription of both TNFAIP3 and C13orf25 was induced by TNFα (Figures 5A and 
B). Interestingly, the significant upregulation of TNFAIP3 protein (Figures 5C and D) was much 
weaker than at the mRNA level suggesting that the efficiency of translation was reduced under these 
conditions. This may, at least in part, be due to the concomitant upregulation of miR-17-92, in 
particular of miR-18a, and thus simultaneous translational repression of TNFAIP3. A similar scenario 
has been suggested previously for the relationship of c-Myc-induced miR-17-92 and its target E2F 
leading to diminished induction of E2F protein compared to the corresponding mRNA (178). 
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Silencing of TNFAIP3 mimics the miR-18a-mediated effects in RASF 
Having demonstrated that TNFAIP3 is a direct target of miR-18a in RASF, we addressed 
whether silencing of this NF-κB inhibitory gene could mimic the effects of miR-18a on MMP1 and 
cytokine expression. Therefore we transfected RASF with siRNAs targeting TNFAIP3, stimulated the 
cells with TNFα and measured target genes by real-time PCR. Figure 6A demonstrates that TNFAIP3 
silencing could be achieved efficiently. Under unstimulated conditions, silencing of TNFAIP3 in- 
  
 
Figure 6 The TNFα-induced miR-18a enhances RASF activation through a positive feedback loop 
in NF-κB signaling via TNFAIP3. 
A and B. RASF (n=8) transfected with siRNA targeting TNFAIP3 were stimulated with TNFα for 24h. A. 
TNFAIP3 expression was efficiently silenced. B. Silencing of TNFAIP3 increased constitutive levels of IL6, IL8 
and RANTES mRNA while the TNFα-induced expression of all five genes studied was enhanced. C. RASF 
(n=8) transfected with a NF-κB responsive reporter vector and pre-miR-18a showed stronger activation of NF-
κB signal transduction than scr-transfected RASF. Data are presented as mean±SD. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 by paired t-test or Wilcoxon matched-pairs signed rank test. D. Model of the 
signaling events in RASF involving miR-18.  
Figure 5 Expression kinetics of TNFAIP3 
and C13orf25 in TNFα-stimulated RASF. 
 RASF (n=8) were stimulated with TNFα for 
8h, 16h and 24h. mRNA levels of TNFAIP3 
(A), C13orf25 (B) and protein levels of 
TNFAIP3 (C, representative Western blot 
image in D) were induced by TNFα. Data are 
presented as mean±SD. **p<0.01, ***p<0.001 
by paired t-test or Wilcoxon matched-pairs 
signed rank test. 
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creased the mRNA levels of IL6, IL8 and RANTES whereas MMP1 and MCP1 mRNA levels were 
not significantly affected. In contrast, under TNFα stimulation, silencing of TNFAIP3 increased the 
expression of all five genes studied (Figure 6B). 
 
The TNFα-induced activation of NF-κB signaling is enhanced by miR-18a 
Finally, we sought to investigate whether miR-18a could influence NF-κB signaling in RASF as 
suggested by the repression of the NF-κB pathway inhibitor TNFAIP3. As expected, RASF 
transfected with miR-18a displayed a stronger constitutive as well as TNFα-induced NF-κB activity 
(Figure 6C).  
Taken together, we suggest the following model of the signaling events involving miR-18a in 
RASF (Figure 6D). Chronic synovial inflammation as simulated in vitro by TNFα induces activation 
of NF-κB and, in turn, upregulation of miR-18a and TNFAIP3. In a negative feedback loop, TNFAIP3 
terminates the action of NF-κB. Repression of TNFAIP3 by miR-18a interferes with this feedback 
loop resulting in enhanced expression of downstream effector genes. 
 
5. Discussion 
 
In this work we have shown that i) the miR-17-92 cluster is induced in RASF by TNFα through 
activation of NF-κB, and ii), that miR-18a is involved in the upregulation of both constitutive and 
TNFα-induced secretion of MMP1 and inflammatory cytokines and chemokines and, thus, increases 
the chemoattractive potential of RASF. Moreover, iii) using reporter gene assays we have identified 
TNFAIP3 as a novel direct target of miR-18a and we could demonstrate that iv) by repressing 
TNFAIP3 expression miR-18a enhances NF-κB signaling in RASF. In conclusion, miR-18a 
constitutes a novel positive feedback loop of the NF-κB signaling pathway via translational repression 
of TNFAIP3 (Figure 6D) which might further aggravate the activated phenotype of SF in the 
pathogenesis of RA.  
In recent years it has become clear that miRNAs are dysregulated in RA and, acting as 
repressors of gene expression, contribute to autoimmunity and joint destruction (reviewed in (176)). 
The miR-17-92 cluster has been associated with important inflammatory processes such as the acute-
phase response (145) and maturation of the immune system. Xiao and colleagues, for example, have 
shown that overexpression of miR-17-92 in lymphocytes of mice led to the development of 
autoimmunity reflected by autoantibody production and lymphocytic infiltrates into nonlymphoid 
tissues (171). In a mouse model of systemic lupus erythematosus miR-17-92 was found to be 
specifically upregulated in splenic T cells (187) and another study showed that miR-17 and miR-19b 
are critical regulators of Th1 responses and Treg differentiation (188). Here we found an upregulation 
of the miR-17-92 primary transcript and its mature miRNAs in response to TNFα, which, in turn, 
repressed the NF-κB pathway inhibitor TNFAIP3 thus mediating proinflammatory functions in our 
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experiments. A recent study, on the other hand, found miR-19a and -19b to be repressed in RASF by 
stimulation with Toll-like receptor (TLR)2 and TLR4 ligands; moreover, TLR2 was identified as a 
direct target of the miR-19 family (189). Thus it may be assumed that different signals connected to 
the pathogenesis of RA might lead to a differential expression and function of miR-17-92 in RASF. 
Interestingly, miR-19a, similar to miR-18a, is predicted to target TNFAIP3 (www.targetscan.org) and 
our own unpublished data using reporter gene assays with the TNFAIP3 3’UTR confirmed this 
prediction. Furthermore, miR-19 was shown to repress the NF-κB inhibitor CYLD (190) and Gantier 
and colleagues very recently found that miR-19b does not only target TNFAIP3 but also other 
negative regulators of NF-κB signaling (191). Based on these findings we strongly argue for a 
proinflammatory role of miR-17-92 in the pathogenesis of RA.  
In our screening to detect a functional role for miR-17-92 in RASF we chose MMP1 expression 
as read-out and found that miR-18a had significant effects on MMP1 mRNA levels; further analysis 
showed that miR-18a also enhances the expression of other important mediators involved in the 
pathogenesis of RA, including IL-6, IL-8, MCP-1 and RANTES. Based on these findings together 
with data from our previous work showing that miR-18a targets the signal transducer and activator of 
transcription (STAT)3 signaling inhibitor PIAS3 (protein inhibitor of activated STAT, 3) (145) we 
postulated that miR-18a similarly might target inhibitors of TNFα-induced signaling pathways and 
found, by a computational approach using TargetScan and subsequent validation experiments, that 
miR-18a acts as a repressor of TNFAIP3. Interestingly, it has been shown that knockout of TNFAIP3 
in myeloid cells triggers the development of an erosive polyarthritis (66); conversely, adenoviral 
delivery of TNFAIP3 improved inflammation and bone destruction in collagen-induced arthritis (67). 
These data show that the NF-κB signaling pathway is a crucial mediator of arthritis and imply that 
controlling NF-κB activity (directly via TNFAIP3 or indirectly through miR-18a) in the different cell 
types involved in the pathogenesis of RA may be a promising therapeutic approach.  
Beside TNFAIP3 we also identified PTP4A3 as a new target of miR-18a by reporter gene assay. 
However, pre-miR-18a transfection did not reduce PTP4A3 levels in RASF. Generally, target 
repression by miRNAs through the miRNA-induced silencing complex may be additionally regulated 
by RNA-binding proteins that facilitate or inhibit the miRNA-mRNA interaction depending on 
different cellular and environmental conditions (110). One might speculate that the functional 
discrepancy observed between PTP4A3 3’UTR targeting by miR-18a in Hek293 and in RASF result 
from the different cellular environment. In conclusion, it appears that repression of TNFAIP3 is the 
major contributor to the miR-18a-mediated upregulation of MMP1 and inflammatory cytokines. 
Silencing of TNFAIP3, however, did not copy the effects of miR-18a transfection completely as 
shown strikingly by experiments on IL8. miR-18a increased the expression of IL8 only when cells 
were stimulated with TNFα, whereas silencing of TNFAIP3 additionally upregulated the constitutive 
IL8 mRNA expression. These results implicate that additional, yet unidentified targets of miR-18a 
may be responsible for the final output in gene expression observed after pre-miR-18a transfection. 
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One such target may be connective tissue growth factor, which was shown to be de-repressed by anti-
miR-18a treatment in glioblastoma spheroid cultures (192) and which has been connected to IL-6 and 
IL-8 expression in tendon fibroblasts (193). The involvement of connective tissue growth factor in 
MMP1 and cytokine expression in RASF remains elusive for the moment and warrants further 
experimental address.     
We showed here for the first time that miR-18a is part of a positive regulatory loop in NF-κB 
signaling in RASF. Work from recent years has established a complex network of miRNAs positively 
and negatively regulating NF-κB signaling at different levels of the signaling cascade (reviewed in 
(194)). Two of those miRNAs that have been associated with the pathogenesis of RA are miR-146a 
and miR-155, of which the latter one is involved in the production of proinflammatory cytokines and 
the development of collagen-induced arthritis (122, 127, 129, 140). They are both induced through 
NF-κB-dependent pathways, but seem to be engaged in negative feedback loops. MiR-155, for 
instance, may repress inflammatory signaling by targeting the inhibitor of κB kinases β and ε (138). 
Together, these data support the importance of an intact NF-κB signaling; different levels of regulation 
appear to include the involvement of various miRNAs to result in a finely balanced activation pattern 
that becomes disturbed under pathological conditions such as RA. 
In conclusion, together with our previous data (145) this work underscores the role of miR-18a 
as a regulator of intracellular signaling pathways that acts as an endogenous amplifier of extracellular 
signals. Further work is needed to complete the picture of miR-18a function in cell signaling and to 
unravel in more detail the role of miR-17-92 in autoimmune diseases, particularly in RA. 
Nevertheless, we have shown that miR-18a is induced by TNFα and is part of a positive feedback loop 
in the NF-κB signaling pathway in RASF; miR-18a thus increases MMP and cytokine expression and 
enhances the chemoattractive potential of RASF by potentiating the effect of TNFα. These data 
suggest that miR-17-92 plays an important role in TNFα-mediated signaling mechanisms which, 
although not directly evidenced by our experiments, might result in RASF-mediated cartilage 
destruction and immune cell infiltration of the joint in the pathogenesis of RA. 
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1. Long noncoding RNAs and epigenetic regulation in RASF 
 
Although only about 2% of the genetic material codes for protein practically the entire genome 
is transcribed making up a large pool of noncoding RNA (71). Small noncoding RNAs include 
miRNAs, snRNAs, snoRNAs, tRNAs and piwi-interacting RNAs, each of them with well-established 
functions in gene regulation. Long noncoding RNAs (lncRNAs) have only recently been recognised as 
regulators of gene expression instead of being genetic junk (73). In the context of this doctoral thesis 
one lncRNA appeared to be of special interest, the HOX transcript antisense intergenic RNA 
(HOTAIR). In an attempt to elucidate the mechanisms of HOTAIR-mediated chromatin remodelling 
Tsai and colleagues identified epigenetic binding partners of HOTAIR, namely EZH2 and the lysine 
specific demethylase 1 (LSD1, an enzyme demethylating H3K4) (195). Folding into extensive 
secondary structures the ~2200 nt-long HOTAIR functions as a modular scaffold that co-ordinately 
localises EZH2 and LSD1 to target chromatin regions causing loss of the activating H3K4me3 mark 
and, simultaneously, gain of the silencing H3K27me3 mark (195). Similar to EZH2, HOTAIR is found 
overexpressed in many human tumours (196) and was shown to promote metastasis by targeting EZH2 
to a certain set of genes inducing gene expression changes that favoured an invasive behaviour of 
cancer cells (197).  
Although expression and function of HOTAIR and other lncRNAs are currently intensively 
studied in the field of cancer research nothing is known about them in autoimmune diseases and 
specifically RA. Hence, in a follow-up project to our previous findings concerning the role of EZH2 in 
RASF (Chapter II, (198)) we wanted to investigate whether HOTAIR (in cooperation with EZH2) 
might contribute to epigenetic dysregulation in RASF, which, in turn, might promote the activated 
phenotype of these cells. 
The first data of this on-going project demonstrated that the expression of HOTAIR was 
strongly reduced in RASF (Figure 1A). Mimicking the inflammatory milieu to which synovial cells 
are exposed within the joint of RA patients, OASF stimulated with TNFα and IL-1β showed 
significantly decreased levels of HOTAIR compared with unstimulated control cells  (Figure 1B). 
Based on the fact that a) EZH2 is upregulated in RASF, b) TNFα stimulation induces the expression 
of EZH2 (198) and c) HOTAIR is encoded in the HOXC gene cluster which is a prime target of EZH2-
mediated gene regulation (72) we hypothesised that HOTAIR expression in SF might be regulated by 
EZH2 and H3K27me3. Overexpression of EZH2 in OASF significantly reduced HOTAIR levels 
(Figure 1C) and ChIP analysis revealed stronger H3K27 trimethylation at the HOTAIR promoter in 
RASF (Figure 1D). Accordingly, H3K27me3 levels at the HOTAIR promoter correlated with the ∆Ct 
values of HOTAIR expression, i.e. the more H3K27me3 was present at the promoter the less it was 
expressed (Figure 1E). Together, these data show that the lncRNA HOTAIR is silenced in RASF due 
to increased EZH2-transferred H3K27me3 mark in its promoter.  
In a next step, we wanted to illuminate the functional consequences of HOTAIR silencing in 
RASF. To this end OASF were transfected with siRNA targeting HOTAIR and the expression of mul-  
Chapter IV – Conclusion and outlook 
 - 68 -  
 
Figure 1 Epigenetic repression of the lncRNA HOTAIR in RASF. 
A. HOTAIR expression is 12.7-fold stronger in OASF (n=13) than in RASF (n=9). B. TNFα- (n=11) and IL-1β- 
(n=5) stimulation reduced the expression of HOTAIR in OASF. C. Transfection of EZH2 silenced the expression 
of HOTAIR in OASF (n=4). D. The promoter of HOTAIR shows increased H3K27me3 levels in RASF (n=16) 
as compared with OASF (n=12). E. The expression of HOTAIR correlates with the promoter H3K27me3 
silencing mark occupancy. 
 
tiple genes involved in the pathogenesis of RA was analysed. mRNA levels of the MMPs 1, 3, 13 and 
14 were significantly increased upon silencing of HOTAIR (Figures 2A, B, C and D). Silencing of 
HOTAIR furthermore increased the TNFα-stimulated induction of MMPs 1, 3 and 13 whereas no sig- 
  
 
Figure 2 HOTAIR silencing increases the expression of matrix-degrading enzymes. 
OASF (n=11) were transfected with siRNA targeting HOTAIR (siHOTAIR) and stimulated with TNFα or IL-1β 
(n=5). The expression of MMP1 (A), MMP3 (B), MMP13 (C) and MMP14 (D) was increased upon HOTAIR 
silencing.  
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nificant difference was seen following stimulation with IL-1β (Figure 2). These data imply that 
HOTAIR might influence TNFα-induced but not IL-1β-induced signalling pathways in RASF. 
Additional experiments are now planned to confirm the effect of HOTAIR silencing on the 
expression of MMPs at the protein level and to further elucidate the mechanisms of HOTAIR 
regulation and HOTAIR function in SF. 
Concerning the regulation of HOTAIR, EZH2 expression in RASF will be silenced using 
siRNA, cells will subsequently be stimulated with TNFα and IL-1β and the expression of HOTAIR 
will be analysed. Chromatin from SF will furthermore be assessed for the H3K27me3 levels at the 
HOTAIR promoter before and after TNFα and IL-1β stimulation using ChIP. These experiments will 
clarify whether TNFα- and IL-1β-mediated repression of HOTAIR depends on the action of EZH2. 
To determine the expression of HOTAIR in vivo, in-situ hybridisation will be performed on RA 
and OA synovial tissue slides. It will further be of interest to address the subcellular localisation of 
HOTAIR; therefore, fluorescence in-situ hybridisation and confocal microscopy will be performed 
using cultured SF.    
To better understand how HOTAIR might regulate MMP expression reportergene assays to 
study the activity of the NF-κB and AP-1 signalling pathways will be carried out using RNA 
interference with EZH2 and HOTAIR in RASF and OASF, respectively. RNA immunoprecipitation 
experiments will illuminate a possible functional interaction of EZH2 with HOTAIR in SF. SF 
stimulated with TNFα and IL-1β will be analysed for their H3K27me3 levels at the MMP promoters. 
To see whether HOTAIR can directly affect the MMP promoter regions further ChIP analyses for 
H3K27me3 will be carried out in HOTAIR-silenced SF. Alternatively, if the MMP promoter 
epigenetic marks are not influenced by manipulating cellular HOTAIR levels possible HOTAIR 
targets may be found in the signalling pathways upstream of MMP induction (i.e. NF-κB and AP-1 
pathways). 
Altogether, this project will complement the data from Chapter II (198) further highlighting the 
importance of epigenetic gene regulation, and of EZH2 in particular, in the activated phenotype of 
RASF. It will furthermore clarify whether lncRNA dysregulation may not only affect malignant 
diseases but also other pathologic conditions such as RA. Thus, this work will contribute to a better 
understanding of the epigenome of RA. 
 
2. EZH2 and miR-17-92 in RASF and the big picture 
 
During my doctorate I have investigated expression and function of a histone methyltransferase 
and a miRNA cluster in the activated phenotype of RASF. In recent years it has become clear that the 
pathogenesis of RA is accompanied by epigenetic dysregulation and differences in the expression of 
miRNAs. Although it is not known yet whether these changes in gene regulation are the cause or the 
consequence of RA it is nevertheless crucial to understand these mechanisms to be able to develop 
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better and targeted therapies in the future. Thus, this work has added new knowledge to a novel and 
exciting field of research substantiating the concept of epigenetic dysregulation and the importance of 
miRNA networks in the activated phenotype of RASF.  
In Chapter II we could show that (i) the histone methyltransferase EZH2 is upregulated in 
RASF, (ii) inducible by TNFα which was dependent on the NF-κB-, JNK- and E2F-Rb pathways, and 
that (iii) the Wnt signalling inhibitor SFRP1 is a target of EZH2-mediated gene silencing in RASF 
(198). In a follow-up project we are currently extending those data by showing that EZH2 also targets 
a lncRNA – HOTAIR – for silencing in RASF (Figure 3).  
 
 
Figure 3 The role of EZH2 in the activated phenotype of RASF 
EZH2 is overexpressed in RASF and is further induced by TNFα. EZH2 overexpression leads to repression of 
SFRP1 and HOTAIR and the gene promoters of SFRP1 and HOTAIR display elevated levels of the repressive 
H3K27me3 mark correlating with their decreased expression. TNFα stimulation further inhibits the expression 
of SFRP1 and HOTAIR implying a possible connection to TNFα-induced EZH2 upregulation. The repression of 
SFRP1 insinuates increased Wnt signalling which, as shown previously, affects the expression of cytokines, 
MMP3 and extracellular matrix molecules in RASF (163, 164). Silencing of HOTAIR results in the upregulation 
of MMPs. 
 
In Chapter III we studied the miR-17-92 cluster and specifically the miR-17-92-derived miR-
18a and found it to be involved in a positive feedback loop in NF-κB signalling in RASF (199). We 
demonstrated that (i) miR-17-92 is induced upon stimulation with TNFα in a NF-κB-dependent 
manner and (ii) miR-18a enhances MMP and inflammatory mediator production by RASF. (iii) 
Validating the NF-κB inhibitor TNFAIP3 as a novel direct target of miR-18a and (iv) showing 
enhanced NF-κB signalling upon pre-miR-18a transfection in RASF we uncovered a new mechanism 
of regulating NF-κB activity as miR-18a interferes with the negative feedback loop of NF-κB-
dependent TNFAIP3 induction (Figure 4).  
At present, no connection is known between EZH2 and miR-17-92. Although miR-17-92 may 
be regulated by epigenetic mechanisms EZH2-mediated H3K27 methylation at the C13orf25 promoter 
has not been studied yet. During Mφ differentiation, miR-17-92 was shown to be epigenetically re- 
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Figure 4 miR-18a is part of a positive feedback loop in NF-κB signalling in RASF 
The NF-κB signal transduction pathway is activated upon stimulation with TNFα which induces the expression 
of inflammatory mediators and matrix-degrading enzymes. TNFα also upregulates TNFAIP3 acting as an 
endogenous inhibitor of NF-κB signalling. The concomitant induction of the miR-17-92 cluster (C13orf25), in 
particular of miR-18a, interferes with this negative feedback loop by the repression of TNFAIP3. The resulting 
increase in NF-κB activity leads to an enhanced expression of cytokines and MMPs. 
 
pressed by the recruitment of a histone demethylase, Jarid1b, and the resulting loss of the H3K4me3 
activating mark (200). In an ACR Abstract 2011 we could demonstrate that miR-196a is repressed in 
RASF due to increased H3K27me3 and decreased H3K4me3 in its promoter (201) thus highlighting 
that EZH2 may indeed regulate miRNAs in SF. The 3’UTR of EZH2 contains miRNA binding sites 
and several miRNAs ( miR-26a, miR-101, miR-124) have been validated as direct regulators of EZH2 
(miRecords http://miRecords.umn.edu/miRecords (202), October 2012). Of interest, miR-124a is 
downregulated in RASF (123) which might contribute to the upregulation of EZH2 in RASF.  Future 
work will have to address the epigenetic mechanisms regulating miR-17-92 and the miRNA-mediated 
mechanisms regulating EZH2 in RASF to fully elucidate how these pathways might be intertwined.  
The aim of translational research as performed during this doctorate should ultimately be the 
transfer to a clinical application, diagnostic or therapeutic. With respect to the roles of EZH2 and miR-
18a in the activated phenotype of RASF both represent potential therapeutic targets. However, the data 
presented here refer to RASF only and more research is indispensable to determine the function of 
both targets in other cell types/compartments involved in the pathogenesis of RA. 
miRNAs may be targeted in vivo by the use of antagomiRs, antisense miRNAs with stabilising 
modifications of the sugar phosphate backbone and a cholesterol moiety at the 3’ end for better 
bioavailability (203). We have previously used antagomiR-20a to successfully prevent vascular 
remodelling and right heart hypertrophy in the hypoxic mouse model of pulmonary hypertension 
(144). Based on our data that miR-18a regulates essential inflammatory signal transduction pathways 
such as STAT3 (145) and NF-κB signaling (199) it might be interesting to test antagomiR-18a in an 
animal model of an inflammatory disease such as RA. Since the mentioned pathways are not just 
involved in RASF activation but also in other cell types important for the pathogenesis of RA (e.g. 
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monocytes, Mφ, osteoclasts) antagomiR-18a might be an attractive tool of affecting all cellular 
compartments of RA simultaneously. Whether targeting miRNAs will be suitable for the treatment of 
human diseases is still an open question. So far, only one miRNA-based treatment strategy has entered 
phase II clinical trials – a miR-122 inhibitor for the treatment of Hepatitis C 
(“miravirsen”, www.santaris.com). As with every other drug the consequences of systemic delivery of 
such a miRNA-based therapy must be carefully examined (204). Since miR-122 is expressed only in 
hepatic tissue antagonising miR-122 with miravirsen may cause less problems of unwanted effects in 
non-target organs, whereas targeting non-organ-specific miRNAs may be associated with serious 
adverse events. At the same time, the bioavailability of miRNA-based drugs is a problem. In 
comparison to small molecule inhibitors an antagomiR is much larger and delivering it to peripheral 
tissues such as the joint may prove challenging, a problem that might be overcome with intra-articular 
injections. 
Therapeutic targeting of epigenetic mechanisms has already progressed further than miRNA-
targeting therapy. Some drugs inhibiting DNA methylation and histone acetylation are yet FDA 
approved for the treatment of several haematologic malignancies (71, 79). Although an inhibitor for 
H3K27 methylation has been known for several years (5’-deazaneplanocin [DZNep]) its mode of 
action depends on the depletion of PRC2 components rather than direct inhibition of the EZH2-
methylating activity (205). Furthermore, it was shown to inhibit histone methylation globally thereby 
not only decreasing H3K27me3 levels but also reducing H3R2me2, H3K4me3, H3K9me1, H3K9me2, 
H3K79me3 and H4K20me3 (206). The development of specific inhibitors to the enzymes transferring 
and removing the H3K27 methylation marks has only been reported this year. A recent study reported 
the discovery of a specific inhibitor of EZH2, EPZ005687, with ~50-fold selectivity over the closely 
related EZH1 protein and over 500-fold selectivity against 15 other protein methyltransferases (207). 
Although EPZ005687 only proved effective in inhibiting cell growth and inducing apoptosis in 
lymphoma cell lines harbouring activating EZH2 mutations it also reduced global H3K27me3 levels in 
wildtype cell lines (207). Similar results were obtained with the SAM-competitive GSK126 that 
showed more than 1000-fold selectivity over 20 other methyltransferases and was even 150-fold less 
potent towards EZH1 as compared with EZH2 (208). Furthermore, GSK126 efficiently inhibited the 
growth of subcutaneous xenografts of diffuse large B cell lymphoma cell lines and increased the 
overall survival of mice (208). These drugs might therefore represent useful tools to further study the 
importance of H3K27me3 in settings where EZH2 is upregulated and constitute a good basis for the 
development of better wt-EZH2 inhibitors. A small-molecule inhibitor GSK-J1 was found to 
specifically bind to and inhibit the two jumonji family H3K27 demethylases Jmjd3 and UTX (209). 
Treatment of LPS-stimulated human primary Mφ with the GSK-J1 pro-drug GSK-J4 partially 
inhibited inflammatory gene expression and, moreover, blocked the LPS-induced loss of H3K27me3 
at the TNFA promoter. Most importantly, it also impeded TNFα production from RA patient-derived 
Mφ (209). Thus, while several lines of evidence argue for possible beneficial effects of inhibiting 
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H3K27 demethylation in inflammatory conditions such as RA, in particular regarding the role of 
Jmjd3 in the inflammatory gene expression of Mφ (153, 209, 210), others argue for the opposite. Our 
own data demonstrate the upregulation of EZH2 in RASF, constitutively and upon TNFα stimulation 
(198). EZH2 was further shown to positively regulate NF-κB activity in estrogen receptor-negative 
breast cancer most likely due to a direct interaction with the NF-κB components RelA and RelB (211). 
Considering the fact that in RA the balance of bone resorption (osteoclasts) and formation 
(osteoblasts) is skewed towards resorption (27) it is interesting to note that the differentiation of 
osteogenic precursor cells depends on a loss in EZH2 activity which induces osteoblast-specific gene 
expression (212) and, thus, EZH2 inhibition might favour osteoblastogenesis. Furthermore, EZH2 was 
demonstrated to be a critical regulator of tumour angiogenesis being overexpressed in the vasculature 
of ovarian cancer and controlling endothelial cell gene expression (213), tube formation (214), 
migration and invasion (215). Since it is inducible by proangiogenic mediators such as VEGF (213) 
and FGF2 (214), molecules that are abundantly expressed in the RA synovium (35), EZH2 might be 
involved in the pathological synovial angiogenesis of RA. Taken together, it appears that H3K27 
methylation is dysregulated under inflammatory conditions such as RA but the direction in which the 
balance is shifted may be dependent on the cell type studied. Therefore, future in vitro as well as in 
vivo studies using specific inhibitors of EZH2 and Jmjd3/UTX must shed more light on the 
involvement of this epigenetic mark in the pathogenesis of RA and in regulating gene expression in all 
cellular compartments of the RA joint. 
 
In summary, with this doctoral thesis I have for the first time addressed histone methylation and 
the miR-17-92 cluster in the activated phenotype of RASF. We provided data showing that 
upregulation of EZH2 led to the epigenetic silencing of the tumour suppressor SFRP1 and the lncRNA 
HOTAIR contributing to the activation of RASF. Validating the miR-17-92-derived miR-18a as a 
novel direct regulator of TNFAIP3 we could identify a new positive feedback loop in the TNFα-NF-
κB pathway enhancing inflammatory signalling in RASF. 
 The better understanding of epigenetic mechanisms and miRNA regulation in the inflammatory 
and destructive processes of RA will eventually help to establish the basis for the improvement of 
current treatment strategies and/or the development of novel targeted therapies in the future. 
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Abbreviations 
 
ACPA anti-citrullinated protein antibodiy 
ACR American College of Rheumatology 
AP-1 activator protein 1 
bp basepairs 
BSA bovine serum albumin 
CD cluster of differentiation 
ChIP chromatin immunoprecipitation 
CIA collagen-induced arthritis 
CTLA4 cytotoxic T-lymphocyte-associated protein 4 
DAMP danger- or damage-associated molecular pattern 
DKK1 Dickkopf-1 
DMARD disease-modifying antirheumatic drug 
DMEM Dulbecco's modified Eagle's medium 
DNA desoxyribonucleic acid 
DNMT DNA methyltransferase 
DUSP16 dual-specific phosphatase 16 
ECM extracellular matrix 
EED embryonic ectoderm development 
ELISA enzyme-linked immunosorbent assay 
EULAR European League against Rheumatism 
EZH2 Enhancer of Zeste homologue 2 (Drosophila) 
FDA Food and Drug Administration 
FGF fibroblast growth factor 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
HDAC histone deacetylase 
HLA human leukocyte antigen 
HOTAIR HOX transcript antisense intergenic RNA 
HOX homeobox transcription factor 
hTNF tg human TNF transgenic 
IκB Inhibitor of κB 
IKK IκB kinase 
IL interleukin 
IRAK interleukin-1 receptor-associated kinase 
JAK janus kinase 
JNK Jun kinase 
KAT histone lysine acetyltransferase 
kDa kilo Dalton 
KMT histone lysine methyltransferase 
lncRNA long noncoding RNA 
LPS lipopolysaccharide 
MAPK mitogen-activated protein kinase 
MCP1 monocyte chemoattractant protein 1 
Mφ macrophage 
MHC major histocompatibility complex 
miRISC miRNA-induced silencing complex 
miRNA, miR microRNA 
MMP matrix metalloproteinase 
mRNA messenger RNA 
MTX methotrexate 
NF-κB nuclear factor kappa B 
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NSAID non-steroidal anti-inflammatory drug 
nt nucleotide 
OA osteoarthritis 
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PDGF platelet-derived growth factor 
PRC polycomb repressor complex 
pre-miRNA precursor miRNA 
pri-miRNA primary miRNA transcript 
PTEN phosphatase and tensin homologue 
PTM posttranslational modification 
PTP4A3 protein tyrosine phosphatase type IV, member 3 
qPCR quantitative real-time PCR 
RA rheumatoid arthritis 
RANKL receptor activator of NF-κB ligand 
RF rheumatoid factor 
RNA ribonucleic acid 
SD standard deviation 
SF synovial fibroblast 
siRNA small interfering RNA 
SLE systemic lupus erythrematosus 
SNP single nucleotide polymorphism 
STAT signal transducer and activator of transcription 
SUZ12 Suppressor of Zeste 12 homologue (Drosophila) 
TGF-β transforming growth factor beta 
Th T helper cell 
TLR toll-like receptor 
TNFα tumour necrosis factor alpha 
TNFAIP3 TNFα-induced protein 3 (A20) 
TSS transcription start site 
UTR untranslated region 
VEGF vascular endothelial growth factor 
Wnt wingless-type MMTV integration site 
XIAP X-linked inhibitor of apoptosis 
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